Finex Pulse • Market Signal Briefing

Details	Saved	Published	Title	Source	Tickers
	2025-11-05 09:24 4mo ago	2025-11-05 03:51 4mo ago	Novo Nordisk accepts Ozempic, Wegovy and Rybelsus prices in US Medicare negotiations	stocknewsapi	NVO
A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. REUTERS/Tom Little/File Photo Purchase Licensing Rights, opens new tab CompaniesLONDON, Nov 5 (Reuters) - Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes and obesity medicines Ozempic, Wegovy and Rybelsus, which will become effective in January 2027. Novo made the disclosure in its quarterly earnings report. Sign up here. The price negotiation process was established under President Biden's signature IRA in 2022. Novo's drugs are among 15 selected as the second group of medications undergoing the process, and are among the most expensive for the Medicare health program for people aged 65 and older or with disabilities. Reporting by Maggie Fick; Editing by Jan Harvey Our Standards: The Thomson Reuters Trust Principles., opens new tab
	2025-11-05 09:24 4mo ago	2025-11-05 03:52 4mo ago	AI Sales May Soar 600% by 2028: 2 Brilliant AI Stocks to Buy Now, According to Wall Street	stocknewsapi	DDOG GOOG GOOGL
Explosive growth in artificial intelligence spending creates an opportunity for patient investors. Capital spending related to artificial intelligence (AI) added more than a percentage point to U.S. economic growth during the first half of 2025, surpassing consumer spending as the primary source of expansion. But Evercore analyst Julian Emanuel says the bull market is far from over, calling AI the most transformative technology since the internet. Indeed, Morgan Stanley analysts estimate AI sales across cloud and software companies will grow more than 600% to surpass $1 trillion annually by 2028. Investors can lean into that trend by purchasing shares of Alphabet (GOOGL 2.18%) (GOOG 2.13%) and Datadog (DDOG 2.82%). Analysts are generally bullish on both stocks: Among 73 analysts, Alphabet has a median target price of $330 per share. That implies 19% upside from its current share price of $278. Among 46 analysts, Datadog has a median target price of $170 per share. That implies 10% upside from its current share price of $155. Read on to learn about these AI stocks. Image source: Getty Images. 1. Alphabet Alphabet is the largest adtech company in the world due to its ability to engage internet users and source consumer data through platforms like Google Search and YouTube. The search market is undoubtedly shifting toward artificial intelligence (AI) tools like Perplexity and ChatGPT, but Alphabet is leaning into the trend with its own generative AI overviews. Alphabet's Google also runs the third-largest public cloud in terms of cloud infrastructure and platform services (CIPS). The company accounted for 13% of CIPS revenue in the third quarter, up a percentage point from where it started the year. As a recognized leader in AI infrastructure and large language models, Google is well positioned to continue gaining share as AI demand increases. Alphabet recently reported solid third-quarter financial results that beat estimates on the top and bottom lines. Revenue increased 16% to $102 billion, an acceleration from 15% growth in the same period last year, and generally accepted accounting principles (GAAP) earnings increased 35% to $2.87 per diluted share. CFO Anat Ashkenazi highlighted strong demand for AI infrastructure, specifically calling attention to interest in custom chips and Gemini models. Wall Street estimates Alphabet's earnings will increase at 15% annually over the next three years. That makes the current valuation of 27 times earnings look reasonable. Investors should feel comfortable buying a small position in this AI stock today. Today's Change ( -2.18 %) $ -6.18 Current Price $ 277.54 2. Datadog Datadog develops observability software. Its platform includes about two dozen products that help businesses monitor the performance of critical IT infrastructure and applications. It also features an artificial intelligence engine called Watchdog that automates anomaly detection, incident alerts, and root cause analysis to help operations teams resolve problems more quickly. The artificial intelligence revolution should be a tailwind for Datadog. Forrester Research recently recognized the company as a leader in AI for IT operations, a technology that leans on automation to help IT teams keep enterprise software and services functional. Gartner has also recognized the company as a leader in observability platforms, citing its ability to support generative AI workloads. Datadog reported encouraging second-quarter financial results that beat estimates on the top and bottom lines. Revenue rose 28% to $827 million, and non-GAAP earnings increased 7% to $0.46 per diluted share. CEO Olivier Pomel highlighted momentum with new AI agents that automate incident response, coding, and security event triage. Wall Street estimates Datadog's adjusted earnings will grow at 19% annually through 2028. That makes the current valuation of 84 times earnings look expensive. But I think analysts have missed the mark. Datadog beat the consensus earnings estimate by an average of 15% over the last six quarters. That pattern is likely to continue as the company focuses on cost savings and gradually pulls back on R&D spending. Investors with a time horizon of at least three years to five years should feel comfortable buying a small position today. If the stock price drops 15%-plus at some point in the future, consider building a slightly larger position. Trevor Jennewine has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Datadog, and Evercore. The Motley Fool recommends Gartner. The Motley Fool has a disclosure policy.
	2025-11-05 09:24 4mo ago	2025-11-05 03:54 4mo ago	Municipal Bonds: I'm Choosing HYMB Over HYD	stocknewsapi	HYD HYMB
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
	2025-11-05 09:24 4mo ago	2025-11-05 03:55 4mo ago	Michael Burry of "The Big Short" Fame and Warren Buffett Have Piled Into This Dirt Cheap but Troubled Stock. Should You Follow?	stocknewsapi	UNH
This company's recovery story is picking up momentum. Before buying or selling a stock, it's important to consider your own investment style instead of following the crowd. But this doesn't mean you shouldn't look around at what others are doing -- especially if they are investors who have proven their abilities over time. You won't follow their every move, but certain ones could offer you inspiration. Two such investors are Michael Burry and Warren Buffett. Burry took the spotlight when he bet against the U.S. housing market prior to the subprime crash -- and made more than $700 million for clients of his hedge fund. The story was brought to the silver screen in the movie The Big Short a few years ago. As for Buffett, he's been wowing the market for nearly 60 years. Over that time period, at the head of Berkshire Hathaway, the billionaire has delivered market-beating returns -- and his words of wisdom have guided investors through any market environment. Burry could be seen as more of an aggressive investor, while Buffett as more cautious, but these two market stars have one thing in common. They don't follow the crowd. And in recent times, that's led them both to invest in a dirt cheap but troubled stock. Now, the question is: Should you follow their lead? Let's find out. Image source: Getty Images. A leader in its industry The company Burry and Buffett have invested in is one that's a leader in its industry but has suffered a few setbacks over the past year. I'm talking about UnitedHealth Group (UNH 0.89%). The biggest U.S. health insurer reported disappointing earnings in the first two quarters of this year, unexpectedly lost its chief executive officer, and faced a Department of Justice probe into its Medicare billing processes. Still, in the second quarter of the year, Burry and Buffett opened positions in UnitedHealth. Burry purchased 20,000 shares and also bought 350,000 in call options -- this type of option, allowing the investor to buy the stock at a certain price before a set time, is a bet that the stock price will rise. Buffett bought 5,039,564 UnitedHealth shares in the quarter. Today's Change ( -0.89 %) $ -2.96 Current Price $ 330.83 UnitedHealth saw its valuation drop during that three-month period, so it's possible these investing experts bought shares at an interesting price. UNH PE Ratio (Forward) data by YCharts And, today, trading at 20x forward earnings estimates, the stock could be considered dirt cheap -- if we're optimistic about the company recovering from current troubles and returning to growth. Identifying problems and taking action So now the question is: Should we be optimistic about the UnitedHealth recovery story and follow Burry and Buffett into the stock? Though it will take some time for UnitedHealth to turn things around, the good news is the company has spotted the problems, is addressing them, and already is making progress. UnitedHealth said earnings weakness mainly has been due to mispricing and market positioning -- the positive point here is these are two elements the company can control. In the recent earnings report, UnitedHealth said repricing within the insurance business -- UnitedHealthcare -- should drive operating earnings growth next year. The company says its efforts to boost the Optum business -- which provides services such as pharmacy care -- will show results next year and thereafter. For example, in Optum Health, the company aims to narrow the provider network, which had grown too wide. Raising 2025 guidance As a result of UnitedHealth's recent moves, the company reported double-digit revenue growth to more than $113 billion and net income that surpassed analysts' estimates. The company also lifted its 2025 guidance to at least $14.90 per share. That's up from an earlier forecast of $14.65 per share. UnitedHealth is showing that it's on the right path to recovery and growth, and at the same time, the stock is very reasonably priced at the moment. It's important to remember that the company is a dominant player in the U.S. and the combination of its insurance and services businesses represents a moat or competitive advantage. All of this offers us reason to be confident about this player's long-term story. Both Burry and Buffett earlier in the year recognized UnitedHealth's potential -- and the good news is that now it's not too late for other investors to follow them into this healthcare stock.
	2025-11-05 09:24 4mo ago	2025-11-05 03:56 4mo ago	Invesco International Small-Mid Company Fund Q3 2025 Portfolio Positioning	stocknewsapi	BLHWF DSRLF MTRAF NURAF TCCPY WOLWF WRTBF
SummaryInvesco International Small-Mid Company Fund added six new positions and exited 11 positions during the quarter.We are benchmark independent, bottom-up investors, focusing on company fundamentals rather than using a “top-down” perspective to overweight or underweight any sector or region.We exited AIA Engineering, Belimo, Epiroc, Japan Elevator Service, Kardex, Konami, and Triveni Turbine. We Are/DigitalVision via Getty Images The following segment was excerpted from Invesco International Small-Mid Company Fund Q3 2025 Commentary. Portfolio positioning We are benchmark independent, bottom-up investors, focusing on company fundamentals rather than using a “top-down” perspective to overweight or underweight any sector Recommended For You
	2025-11-05 09:24 4mo ago	2025-11-05 03:57 4mo ago	Where Will Chime Financial Stock Be in 5 Years?	stocknewsapi	CHYM
This little fintech has a lot of growth potential. Chime Financial (CHYM 0.25%) hasn't impressed many investors since its initial public offering (IPO) this June. The provider of mobile banking services went public at $27 a share, but it now trades at around $17. Chime's business is still growing, but a sequential slowdown in its latest quarter spooked the bulls. Does that pullback represent a good buying opportunity for investors who want to hold its stock for at least five years? Let's review its business model and near-term challenges to decide. Image source: Getty Images. How does Chime differ from traditional banks? Chime provides no-fee checking and savings accounts with overdraft protection, early-pay features (earlier access to direct deposits), and other financial services. It also issues a Visa debit card with no-fee access to over 50,000 ATMs and an entry-level Visa credit card. The company mainly targets lower-income users who don't have enough cash to open higher-value, no-fee accounts at traditional banks. Its early-pay tools are also useful for people who live paycheck to paycheck, while its credit cards help them gradually build up their credit scores. Today's Change ( -0.25 %) $ -0.04 Current Price $ 17.80 But Chime isn't a bank. Its fintech platform streamlines the online banking services from two federally-insured banks: The Bancorp and Stride Bank. These two banks hold and manage all of Chime's accounts. The company generates most of its revenue by taking a cut of the swipe fees that Visa charges businesses whenever its debit and credit cards are used. A smaller percentage comes from the incentives paid by its banking partners for drawing in more customers. Did investors overreact to Chime's slowdown? Chime's growth can be gauged by its number of active members, the purchase volumes on its cards, and its average revenue per active member (ARPAM). Those metrics rose in 2023 and 2024, but its purchase volume and ARPAM dipped sequentially in the second quarter of 2025: Metric 2023 2024 Q1 2025 Q2 2025 Active members 6.6 million 8 million 8.6 million 8.7 million Member growth (YOY) 25% 21% 23% 23% Purchase volume $92.4 billion $115.2 billion $34.5 billion $32.4 billion Volume growth (YOY) 29% 25% 18% 18% ARPAM $212 $245 $251 $245 ARPAM growth (YOY) 1% 16% 9% 12% Revenue $1.28 billion $1.67 billion $519 million $528 million Revenue growth (YOY) 27% 31% 32% 37% Data source: Chime Financial. YOY = Year over year. Management attributed that sequential slowdown to its seasonal headwinds, since tax refunds often drive more spending in the first quarter of each year. That was certainly true last year: In the second quarter of 2024, its total purchase volume and ARPAM declined 3% and 6%, respectively, on a sequential basis. Therefore, that slowdown shouldn't be considered a bright red flag yet. However, the margin under adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) -- which finally broke even in 2024 and expanded to 5% in the first quarter of 2025 -- still dipped sequentially to 3% in the second quarter as it ramped up its marketing campaigns and expanded its ecosystem with lower-margin features. That mix of slower growth and higher expenses likely disappointed its growth-focused investors, but the near-term outlook indicates its core business is still firing on all cylinders. For the full year, it expects its revenue to rise from 28% to 29% as its adjusted EBITDA margin expands to 4%. Where will Chime's stock be in five years? From 2024 to 2027, analysts expect Chime's revenue to show a compound annual growth rate (CAGR) of 23% to $3.1 billion. They expect its adjusted EBITDA to turn positive in 2025 with a CAGR of 125% to $455 million in 2027. With an enterprise value of $5.4 billion, it still looks undervalued at 2 times next year's sales and 20 times its adjusted EBITDA. Chime still faces plenty of competition from other fintech apps, like PayPal and Block's Cash App, but there could be plenty of room for these platforms to expand without trampling one another. All of them should continue to pull lower-income customers away from bigger banks, especially if the broader economy weakens. Assuming Chime matches analysts' estimates through 2027, has a CAGR of 20% through 2031 for revenue, and trades at a more generous 5 times forward sales, its stock could surge nearly sixfold within the next five years and boost its enterprise value to $32.2 billion. So if you believe it can hit those targets as it widens its moat against its competitors, then it's a good idea to accumulate more shares of this fintech as it stagnates below its IPO price.
	2025-11-05 09:24 4mo ago	2025-11-05 03:57 4mo ago	Rocket Companies: First End-To-End Mortgage Ecosystem And AI-Driven Efficiency	stocknewsapi	RKT
SummaryRocket Companies is rated a Buy, driven by strong financial momentum, strategic acquisitions, and positive macroeconomic expectations.Recent acquisitions of Redfin and Mr. Cooper create an end-to-end home-buying ecosystem, boosting revenue stability and client recapture.RKT's diversified revenue streams and AI-driven efficiencies position it to benefit from anticipated interest rate cuts and future market recovery.Despite traditional overvaluation metrics, robust growth prospects, and operational leverage, RKT is a compelling long-term investment opportunity. Getty Images Investment Thesis Rocket Companies, Inc. (RKT) delivered a double beat, reporting EPS of $0.07 and revenue of $1.78 billion. As a result, the company’s stock rose by 5.65% on the day of the earnings release. My thesis Analyst’s Disclosure:I/we have a beneficial long position in the shares of RKT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. Recommended For You
	2025-11-05 09:24 4mo ago	2025-11-05 03:59 4mo ago	Invesco International Small-Mid Company Fund Q3 2025 Top Contributors And Detractors	stocknewsapi	CZMWF ICLR IMCDY LGRDY PNDZF RADLY SSMXY
Comments SummaryInvesco International Small-Mid Company Fund outperformed most in the real estate and consumer staples sectors due to stock selection.The fund’s underweight in real estate also added to relative return.The fund underperformed most in healthcare, information technology and materials due to stock selection.Invesco is an independent investment management firm dedicated to delivering an investment experience that helps people get more out of life.Be the first to know! Sign up for Invesco US Blog and get expert investment views as they post.Disclosure for all Invesco US articles: Before investing, carefully read the prospectus and/or summary prospectus and carefully consider the investment objectives, risks, charges and expenses. The information provided is for educational purposes only and does not constitute a recommendation of the suitability of any investment strategy for a particular investor. Invesco does not provide tax advice. The tax information contained herein is general and is not exhaustive by nature. Federal and state tax laws are complex and constantly changing. Investors should always consult their own legal or tax professional for information concerning their individual situation. The opinions expressed are those of the authors, are based on current market conditions and are subject to change without notice. These opinions may differ from those of other Invesco investment professionals. NOT FDIC INSURED MAY LOSE VALUE NO BANK GUARANTEE All data provided by Invesco unless otherwise noted. Invesco Distributors, Inc. is the US distributor for Invesco Ltd.’s retail products and collective trust funds. Invesco Advisers, Inc. and other affiliated investment advisers mentioned provide investment advisory services and do not sell securities. Invesco Unit Investment Trusts are distributed by the sponsor, Invesco Capital Markets, Inc., and broker-dealers including Invesco Distributors, Inc. PowerShares® is a registered trademark of Invesco PowerShares Capital Management LLC (Invesco PowerShares). Each entity is an indirect, wholly owned subsidiary of Invesco Ltd. ©2015 Invesco Ltd. All rights reserved. Recommended For You
	2025-11-05 09:24 4mo ago	2025-11-05 04:00 4mo ago	Oculis to Participate in Upcoming November Investor Conferences	stocknewsapi	OCS
November 05, 2025 04:00 ET \| Source: Oculis Holding AG ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, announced today that Oculis’ management will participate in upcoming investor conferences in November. Oculis is pleased to present updates of its innovative, highly differentiated, late-stage portfolio as it enters a pivotal phase in its transformation into a leader in neuro-ophthalmology and ophthalmology. Key highlights include: Privosegtor (PIONEER program) advancement into registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION), following a positive FDA meeting; OCS-01 (DIAMOND registrational trials) topline results for diabetic macular edema expected in Q2 2026; and Licaminlimab (PREDICT-1 registrational trial) in DED anticipated soon, marking the first genotype-based development program to drive precision medicine. With a strong balance sheet and robust pipeline, Oculis is well-positioned to deliver 6 pivotal readouts with the current funding, to fulfil its mission to save sight and improve eye care with groundbreaking treatments. Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10-12; Boston, U.S. Fireside chat with Riad Sherif, M.D., Chief Executive Officer, on November 11th at 2:30 pm ET. Webcast link: Register here. Stifel Healthcare Conference November 11-13; New York, U.S. Fireside chat with Riad Sherif, M.D., Chief Executive Officer, on November 12th at 2:00 pm ET. Webcast link: Register here. LifeSci Capital and Sofinnova Partners Growth & Innovation Summit November 17; London, U.K. Oculis management will participate in one-to-one meetings. ICR Healthcare and Sponsors 13th Annual Healthcare Conference November 17; London, U.K. Riad Sherif, M.D., Chief Executive Officer, will participate in a panel discussion, entitled ‘Brave New World,’ at 1:50 pm GMT. The company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings. Webcast links, when available, will be posted to the Oculis website on the Events & Presentation page under the Investors & Media section. About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing neuro-ophthalmic conditions with significant unmet medical needs. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: Privosegtor, a neuroprotective candidate in the PIONEER program which consists of studies intended to support registration plans for treatment in optic neuropathies like acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases; OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNFα in Phase 2, which is being developed with a genotype-based approach to drive precision medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. For more information, please visit: www.oculis.com Oculis Contact Ms. Sylvia Cheung, CFO [email protected] Investor Relations LifeSci Advisors Corey Davis, Ph.D. [email protected] Media Relations ICR Healthcare Amber Fennell / David Daley / Sean Leous [email protected] Cautionary Statement Regarding Forward Looking Statements This press release contains forward-looking statements and information. For example, statements regarding the development plans for Privosegtor, OCS-01, and Licaminlimab; the initiation, timing, progress and results of clinical trials of Privosegtor, OCS-01, and Licaminlimab; and Oculis’ research and development programs, regulatory and business strategy, future development plans, and management, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (SEC). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
	2025-11-05 09:24 4mo ago	2025-11-05 04:00 4mo ago	Nissan and Infobip Achieve 200% Increase in Engagement with AI-Driven WhatsApp Campaign	stocknewsapi	NSANY
VODNJAN, Croatia--(BUSINESS WIRE)--Nissan has redefined customer engagement by partnering with global cloud communications platform Infobip to pioneer a first-of-its-kind Agentic AI campaign. Nissan Kingdom of Saudi Arabia (KSA) leveraged Infobip’s newly launched Conversational AI Gamification, an AI-powered toolset that enables playful, immersive experiences across messaging channels. The marketing campaign utilized Infobip's Vocalize feature, an AI-powered voice game where users competed to win a brand-new Nissan Magnite. Participants used their voices to match an audio waveform to the outline of a car, directly within WhatsApp. This innovative approach transformed lead generation into an engaging competition, driving user participation and brand interaction. For Nissan KSA, the campaign enhanced brand awareness, increased engagement time, simplified lead acquisition, and stronger brand affinity. The innovative format also provided a cost-effective acquisition channel through chat-based journeys. The campaign achieved remarkable results: a 200% increase in session engagement, a 68% conversion rate from users reaching the competition stage, over 3,400 chatbot sessions, and 1,000 new user profiles created in 5 days. Ervin Jagatić, AI Business Unit and Product Director at Infobip, said: “Conversational AI Gamification is transforming the way brands can connect with their audiences. By combining AI, voice technology, and gamification, we're enabling global companies like Nissan to create engaging experiences that drive connections, capture valuable user data, and elevate customer experiences." Karma Al-Ajlani, Deputy General Manager – Customer Experience at Nissan Saudi Arabia, said: “We aimed to boost Magnite awareness and remain top-of-mind. Partnering with Infobip on this pioneering AI-powered WhatsApp voice game has transformed customer engagement; Making it fun, interaction, and rewarding. This demonstrates Nissan Saudi Arabia’s dedication to innovation and superior customer experience.” Conversational AI Gamification includes two key features. Vocalize, an AI-powered voice game where users match their audio to specific patterns or shapes, and Augmentation, which offers seamless transition from chat to immersive digital environments via smartphone cameras. The success of the Nissan KSA campaign underscores Infobip's position as a leader in conversational experiences and AI innovation in marketing engagement. By enabling brands to create these unique, interactive campaigns, Infobip is helping its clients lead in digital transformation and customer engagement. For more information about Infobip: https://www.infobip.com/
	2025-11-05 09:24 4mo ago	2025-11-05 04:00 4mo ago	Oculis to Participate in Upcoming November Investor Conferences	stocknewsapi	OCS
ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, announced today that Oculis’ management will participate in upcoming investor conferences in November. Oculis is pleased to present updates of its innovative, highly differentiated, late-stage portfolio as it enters a pivotal phase in its transformation into a leader in neuro-ophthalmology and ophthalmology. Key highlights include: Privosegtor (PIONEER program) advancement into registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION), following a positive FDA meeting; OCS-01 (DIAMOND registrational trials) topline results for diabetic macular edema expected in Q2 2026; and Licaminlimab (PREDICT-1 registrational trial) in DED anticipated soon, marking the first genotype-based development program to drive precision medicine. With a strong balance sheet and robust pipeline, Oculis is well-positioned to deliver 6 pivotal readouts with the current funding, to fulfil its mission to save sight and improve eye care with groundbreaking treatments. Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10-12; Boston, U.S. Fireside chat with Riad Sherif, M.D., Chief Executive Officer, on November 11th at 2:30 pm ET. Webcast link: Register here. Stifel Healthcare Conference November 11-13; New York, U.S. Fireside chat with Riad Sherif, M.D., Chief Executive Officer, on November 12th at 2:00 pm ET. Webcast link: Register here. LifeSci Capital and Sofinnova Partners Growth & Innovation Summit November 17; London, U.K. Oculis management will participate in one-to-one meetings. ICR Healthcare and Sponsors 13th Annual Healthcare Conference November 17; London, U.K. Riad Sherif, M.D., Chief Executive Officer, will participate in a panel discussion, entitled ‘Brave New World,’ at 1:50 pm GMT. The company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings. Webcast links, when available, will be posted to the Oculis website on the Events & Presentation page under the Investors & Media section. -END- About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing neuro-ophthalmic conditions with significant unmet medical needs. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: Privosegtor, a neuroprotective candidate in the PIONEER program which consists of studies intended to support registration plans for treatment in optic neuropathies like acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases; OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNFα in Phase 2, which is being developed with a genotype-based approach to drive precision medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. For more information, please visit: www.oculis.com Oculis Contact Ms. Sylvia Cheung, CFO [email protected] Investor Relations LifeSci Advisors Corey Davis, Ph.D. [email protected] Media Relations ICR Healthcare Amber Fennell / David Daley / Sean Leous [email protected] Cautionary Statement Regarding Forward Looking Statements This press release contains forward-looking statements and information. For example, statements regarding the development plans for Privosegtor, OCS-01, and Licaminlimab; the initiation, timing, progress and results of clinical trials of Privosegtor, OCS-01, and Licaminlimab; and Oculis’ research and development programs, regulatory and business strategy, future development plans, and management, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (SEC). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
	2025-11-05 09:24 4mo ago	2025-11-05 04:00 4mo ago	Sunlands Technology Group to Report Third Quarter 2025 Financial Results on Thursday, November 20, 2025	stocknewsapi	STG
BEIJING, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sunlands Technology Group (NYSE: STG) ("Sunlands" or the "Company"), a leader in China's adult online education market and China's adult personal interest learning market, today announced that it will report its third quarter 2025 unaudited financial results on Thursday, November 20, 2025, before the open of U.S. markets. Sunlands' management team will host a conference call at 7:00 a.m. U.S. Eastern Time, (8:00 p.m. Beijing/Hong Kong time) on November 20, 2025, following the quarterly results announcement. For participants who wish to join the call, please access the link provided below to complete online registration 30 minutes prior to the scheduled call start time. Upon registration, participants will receive details for the conference call, including dial-in numbers, a personal PIN and an e-mail with detailed instructions to join the conference call. Registration Link: https://register-conf.media-server.com/register/BI8300e40c73ed4950972d9e8dd3b708b8 Additionally, a live webcast and archive of the conference call will be available on the Investor Relations section of Sunlands' website at https://ir.sunlands.com/. About Sunlands Sunlands Technology Group (NYSE: STG) ("Sunlands" or the "Company"), formerly known as Sunlands Online Education Group, is a leader in China's adult online education market and China's adult personal interest learning market. With a one to many, live streaming platform, Sunlands offers online professional courses and educational content, including various interest courses, aimed at preparing students for professional certification exams, enhancing their professional skills, and catering to their personal interests, as well as various degree- or diploma-oriented post-secondary courses. Students can access its services either through PC or mobile applications. The Company's online platform cultivates a personalized, interactive learning environment by featuring a virtual learning community and a vast library of educational content offerings that adapt to the learning habits of its students. Sunlands offers a unique approach to education research and development that organizes subject content into Learning Outcome Trees, the Company's proprietary knowledge management system. Sunlands has a deep understanding of the educational needs of its prospective students and offers solutions that help them achieve their goals. For investor and media inquiries, please contact: Sunlands Technology Group Investor Relations Email: [email protected] SOURCE: Sunlands Technology Group
	2025-11-05 09:24 4mo ago	2025-11-05 04:04 4mo ago	XPeng Gears Up to Launch Robotaxis Next Year	stocknewsapi	XPEV
The Nasdaq-listed company is set to become the first Chinese carmaker to launch a self-developed robotaxi.
	2025-11-05 09:24 4mo ago	2025-11-05 04:05 4mo ago	Orsted swings to quarterly net loss as Trump's offshore wind battle takes its toll	stocknewsapi	DNNGY DOGEF
Danish renewables giant Orsted on Wednesday reported a quarterly net loss as the beleaguered company continues to battle U.S. President Donald Trump's anti-wind policies. The world's biggest offshore wind farm group posted a net loss of 1.7 billion Danish kroner ($261.8 million) for the July-September period. The result, which was slightly better than analysts feared, was significantly down from profit of 5.17 billion Danish kroner in the same period last year. Orsted flagged third-quarter impairment costs of nearly 1.8 billion Danish kroner. The company, however, reiterated its full-year earnings before interest, taxes, depreciation, and amortization (EBITDA) guidance of 24-27 billion Danish kroner, excluding earnings from new partnerships and cancellation fees. It comes shortly after the company announced it had reached a deal to sell a 50% stake in its Hornsea 3 offshore wind farm in the U.K. to Apollo Global Management in a deal worth $6 billion. "I'm satisfied with the good progress across our entire construction portfolio and our solid operational performance," Orsted CEO Rasmus Errboe said in a statement. "Our key focus is to continue delivering on our business plan, which will enable Ørsted to remain a global leader of offshore wind with a strong foothold in Europe," he added. Shares of Orsted were 1.2% higher on Wednesday morning. The stock price has fallen sharply this year amid concerted efforts from the White House to halt several ongoing developments and suspend new licensing.
	2025-11-05 09:24 4mo ago	2025-11-05 04:05 4mo ago	Xenia Hotels Bets On Buybacks Amid Sluggish Recovery	stocknewsapi	XHR
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
	2025-11-05 09:24 4mo ago	2025-11-05 04:06 4mo ago	Petro Matad falls 11% despite new production from Gazelle well	stocknewsapi	PRTDF
Shares in Petro Matad Limited (AIM:MATD, OTC:PRTDF) slipped 11% to 1.4p after the Mongolia-focused oil producer reported mixed operational news, with a new well starting production but continued challenges at another site. The AIM-quoted explorer said its Gazelle-1 well, tested in October, has been brought online at an initial rate of around 200 barrels of oil per day. Early shipments have been delivered to PetroChina under an existing sales agreement, and the company is monitoring performance to see if output can be increased. However, progress at the Heron-2 well has been slower than hoped. After early signs of oil recovery, flow rates dropped due to a possible downhole issue or perforation blockage. Pumping operations have resumed, but if output does not improve, the well will be shut in for the winter. Heron-1, which has now been producing for a year, continues to perform steadily with total output close to 60,000 barrels and a low water cut of about 3%. Petro Matad is also renegotiating payment terms with PetroChina to ensure full and timely settlement for exported crude. Chief executive Mike Buck said production growth and cash generation remain the focus as the company works through operational and contractual hurdles.
	2025-11-05 09:24 4mo ago	2025-11-05 04:14 4mo ago	Scorpio Tankers: Entering A Mature Phase With Stable Dividends Ahead	stocknewsapi	STNG
SummaryScorpio Tankers reported Q3 2025 results showing lower profits but a significantly stronger balance sheet and increased dividend to $0.42 per share.STNG continues aggressive debt reduction, maintains minimal CAPEX, and prioritizes financial stability with cash reserves of $626.7 million and net debt down to $255 million.Despite normalized TCE rates post-2024, the company remains flexible, effective, and undervalued relative to peers, with strong fundamentals and a modern fleet.I rate STNG as a buy, viewing it as a mature, low-leverage dividend stock with upside potential and robust shareholder value support.Dikuch/iStock via Getty Images Scorpio Tankers (STNG) Q3 2025 results gave me some mixed feelings. profitability went down, but the balance became stronger than ever. The company is continuing aggressive debt reduction, accumulates cash and increases its liquidity. CAPEX seems to be moderate Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. Recommended For You
	2025-11-05 09:24 4mo ago	2025-11-05 04:15 4mo ago	Nordea targets return on equity of above 15% in 2026-2030	stocknewsapi	NRBAY
A view of a Nordea logo above one of its branches in Lund, Sweden, October 16, 2023. REUTERS/ Tom Little/File Photo Purchase Licensing Rights, opens new tab CompaniesNov 5 (Reuters) - Nordea (NDAFI.HE), opens new tab, the Nordic region's biggest bank, is targeting a return on equity of above 15% between 2026 and 2030, and significantly above that in 2030, it said in a statement ahead of its investor day on Wednesday. Nordea will target profitable growth in each of its businesses, the bank said, with a special focus in Norway and Sweden, its biggest market. Sign up here. The bank also said it expects a cost-to-income ratio of 40–42% in 2030, excluding regulatory fees. It said the new targets would be supported by a 60–70% annual dividend payout ratio, and semi-annual dividend distributions, and more than 20 billion euros ($23 billion) in total shareholder distributions during 2026-30. The bank's interim dividend will be based upon 50% of its first-half profit for the financial year, it said. Nordea's shares fell around 3% in early trade in Helsinki, the worst performer on the Helsinki blue-chip index (.OMXH25), opens new tab. The bank said that it expects its core tier 1 ratio, a key measure of its financial strength, to about 15.5% throughout the five-year period. ($1 = 0.8575 euros) Reporting by Elviira Luoma in Gdansk, editing by Matt Scuffham Our Standards: The Thomson Reuters Trust Principles., opens new tab
	2025-11-05 09:24 4mo ago	2025-11-05 04:17 4mo ago	Nu Holdings Q3 Preview: Margin Expansion Could Drive The Next Re-Rating	stocknewsapi	NU
Analyst’s Disclosure:I/we have a beneficial long position in the shares of NU, ITUB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
	2025-11-05 09:24 4mo ago	2025-11-05 04:20 4mo ago	Revolve Group, Inc. (RVLV) Q3 2025 Earnings Call Transcript	stocknewsapi	RVLV
Q3: 2025-11-04 Earnings SummaryEPS of $0.30 beats by $0.17 \| Revenue of $295.63M (4.41% Y/Y) misses by $2.10M Revolve Group, Inc. (RVLV) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Erik Randerson - Vice President of Investor Relations Michael Mente - Co-Founder, Co-CEO & Director Michael Karanikolas - Co-Founder, Co-CEO & Chairman of the Board Jesse Timmermans - Chief Financial Officer Conference Call Participants Rakesh Patel - Raymond James & Associates, Inc., Research Division Oliver Chen - TD Cowen, Research Division Matt Koranda - ROTH Capital Partners, LLC, Research Division Michael Binetti - Evercore Inc. Janine Hoffman Stichter - BTIG, LLC, Research Division Anna Andreeva - Piper Sandler & Co., Research Division Kavya Narayanan - Morgan Stanley, Research Division Jay Sole - UBS Investment Bank, Research Division Peter McGoldrick - Stifel, Nicolaus & Company, Incorporated, Research Division Mary Sport - BofA Securities, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. My name is Abby, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Revolve Group Third Quarter 2025 Earnings Call. [Operator Instructions] I would now like to turn the conference over to Erik Randerson, Senior Vice President of Investor Relations. You may begin. Erik Randerson Vice President of Investor Relations Good afternoon, everyone, and thanks for joining us to discuss Revolve's third quarter 2025 results. Before we begin, I'd like to mention that we have posted a presentation containing Q3 2025 financial highlights to our Investor Relations website located at investors.revolve.com. I'd also like to remind you that this conference call will include forward-looking statements, including statements related to our future growth, our inventory balance, our key priorities and business initiatives, industry trends, the impact of tariffs and our mitigation efforts, our marketing events and their expected impact, our physical retail stores and our outlook for net sales, gross margin, operating expenses and effective tax rate. These statements are subject to Recommended For You
	2025-11-05 09:24 4mo ago	2025-11-05 04:20 4mo ago	PTC Therapeutics, Inc. (PTCT) Q3 2025 Earnings Call Transcript	stocknewsapi	PTCT
Q3: 2025-11-04 Earnings SummaryEPS of $0.19 beats by $1.30 \| Revenue of $211.01M (7.23% Y/Y) beats by $35.49M PTC Therapeutics, Inc. (PTCT) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Ellen Cavaleri Matthew Klein - CEO & Director Eric Pauwels - Chief Business Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Tazeen Ahmad - BofA Securities, Research Division Brian Abrahams - RBC Capital Markets, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Judah Frommer - Morgan Stanley, Research Division Yuxi Dong - Jefferies LLC, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Joon Lee - Truist Securities, Inc., Research Division Huidong Wang - Barclays Bank PLC, Research Division Samantha Corwin - William Blair & Company L.L.C., Research Division Joseph Schwartz - Leerink Partners LLC, Research Division John Peyton Bohnsack - TD Cowen, Research Division Luke Herrmann - Robert W. Baird & Co. Incorporated, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Today's call is being recorded. I would now like to turn the call over to Ellen Cavaleri, Head of Investor Relations. Please go ahead. Ellen Cavaleri Good afternoon, and thank you for joining us to discuss PTC Therapeutics' Third Quarter 2025 Corporate Update and Financial Results. I'm joined today by our Chief Executive Officer, Dr. Matthew Klein; our Chief Business Officer, Eric Pauwels; and our Chief Financial Officer, Pierre Gravier. Today's call will include forward-looking statements based on our current expectations. These statements are subject to certain risks and uncertainties, and actual results may differ materially. Please review the slide posted on our Investor Relations website in conjunction with the call, which contains information about our forward-looking statements, our most recent quarterly report on Form 10-Q and annual report on Form 10-K filed with the SEC as well as our other SEC filings Recommended For You
	2025-11-05 09:24 4mo ago	2025-11-05 04:21 4mo ago	Laureate Education: Unlocking Value Through Campus Expansion And Buybacks	stocknewsapi	LAUR
SummaryLaureate Education (LAUR) achieved 8.5% YoY revenue growth in Q3, driven by strong enrollment increases in Mexico and Peru. Enrollment surged 7% YoY, with total YTD enrollments reaching 511,000, supporting a positive outlook for LAUR. Adjusted net income rose 11% YoY, reflecting cost discipline despite margin pressure and the absence of prior-year one-time tax benefits. Share repurchase program expanded by $150MM; $177MM remaining capacity signals undervaluation. Strong Buy maintained on enrollment momentum, expansion pipeline, and undervalued growth outlook. Pgiam/iStock Unreleased via Getty Images I initiated my coverage for Laureate Education Inc. (NASDAQ:LAUR) on August 9. I issued a Strong Buy rating, which turned out to be successful as the stock provided 17.8% return compared to S&P 7.3%. I previously Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. Recommended For You
	2025-11-05 08:24 4mo ago	2025-11-05 02:39 4mo ago	Sinopec Signs Deals Worth US$40.9 Billion at CIIE 2025	stocknewsapi	SNPMF
, /PRNewswire/ -- China Petroleum & Chemical Corporation (HKG: 0386, "Sinopec") hosted a themed forum and a signing ceremony on November 4 at the 8th China International Import Expo (CIIE 2025). The Company signed purchasing contracts with 34 partners from 17 countries and regions, which totaled US$40.9 billion, including 24 products from 10 major categories, including crude oil, chemicals, equipment, materials, consumer goods and more. Since the first CIIE in 2018, Sinopec has signed orders exceeding a total of US$325 billion in eight sessions. Sinopec Signs Deals Worth US$40.9 Billion at CIIE 2025. Centered on the theme Technology Driven, AI Empowered: The Future of Energy, the forum focused on digital intelligence, technological innovation, new materials R&D, supply chain resilience enhancement, and exploring deeper international energy cooperation. Zhao Dong, vice chairman and president of Sinopec, delivered a speech at the forum, which was moderated by Li Yonglin, director and senior vice president of Sinopec. Niu Shuanwen, director and senior vice president of Sinopec, attended the event and signed agreements with international partners. "Sinopec is firmly committed to its primary mission of promoting high‑quality development. While continuing to consolidate the industrial foundation leveraging technological strength, the group also adheres to the principle of 'digital intelligence empowerment' to activate new engines of value creation, striving to advance the energy and chemical industry toward greater sophistication, intelligence, and sustainability," remarked Zhao Dong. He emphasized that Sinopec's development is inseparable from the long‑term trust and strong support of global partners. Looking ahead to China's 15th Five‑Year Plan period, Zhao Dong outlined Sinopec's goal to work with all parties to strengthen scientific and technological innovation, break developmental bottlenecks, and build new industry advantages. Zhao Dong also called for joint efforts to accelerate the pace of digital intelligence empowerment, promote deep integration of next‑generation information technology with the energy and chemical industry, and stimulate new drivers for industrial upgrading. Zhao Dong said Sinopec will expand green and low‑carbon cooperation, advancing clean and efficient use of traditional energy in parallel with the large‑scale development of new energy, thereby creating a sustainable development blueprint and a bright future for the energy and chemical industry. Senior executives from leading firms—Datuk Sazali Hamzah (EVP & CEO Downstream, Petronas Chemicals Group), Axel Lorenz (CEO, Process Automation, Siemens), Aravind Yarlagadda (SVP, Industrial Solutions, Baker Hughes), and Audun M. Martinsen (Partner and Head of Energy Service Research, Rystad Energy)—delivered keynote speeches. SOURCE SINOPEC
	2025-11-05 08:24 4mo ago	2025-11-05 02:39 4mo ago	Alamos Gold: Top-Quality Gold Miner Trading Below Fair Value With Strong Organic Growth	stocknewsapi	AGI
SummaryAlamos Gold remains a Buy, trading below fair value despite a recent production cut and strong gold price gains.AGI boasts a robust financial position, low-cost operations, and a promising organic growth pipeline, targeting ~700,000 ounces by 2027.Temporary setbacks such as the downtime at Magino and Island Gold are not fundamental issues and do not alter the company's long-term potential, but they came at a terrible time.Even if gold prices decline, AGI's organic growth should offset it, while potential for higher gold prices could unlock significant upside for the stock.Analyst’s Disclosure:I/we have a beneficial long position in the shares of AGI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. Recommended For You
	2025-11-05 08:24 4mo ago	2025-11-05 02:41 4mo ago	Orsted Swings to Loss Following U.S. Stop-Work Order, But Stays Upbeat for Full Year	stocknewsapi	DNNGY DOGEF
The renewable-energy company said it remained confident of reaching its full-year targets.
	2025-11-05 08:24 4mo ago	2025-11-05 02:41 4mo ago	French satellite operator Eutelsat taps Imerys exec as next finance chief	stocknewsapi	ETCMY EUTLF IMYSF
Eutelsat has appointed Sébastien Rouge as its new Chief Financial Officer, the French satellite operator said on Wednesday.
	2025-11-05 08:24 4mo ago	2025-11-05 02:42 4mo ago	Nvidia deepens India focus with $2 billion Deep Tech Alliance partnership	stocknewsapi	NVDA
Nvidia is expanding its footprint in India by joining a $2 billion investment alliance focused on deep technology, according to CNBC. As a founding member of the India Deep Tech Alliance (IDTA), the US chipmaker aims to mentor startups building solutions in semiconductors, artificial intelligence, biotechnology, space, robotics, and energy.
	2025-11-05 08:24 4mo ago	2025-11-05 02:44 4mo ago	Johnson Controls Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts	stocknewsapi	JCI
Johnson Controls International plc (NYSE:JCI) will release earnings results for the fourth quarter before the opening bell on Wednesday, Nov. 5. Analysts expect the Cork, Ireland-based company to report quarterly earnings at $1.20 per share, down from $1.28 per share in the year-ago period. The consensus estimate for Johnson Controls' quarterly revenue is $6.33 billion, compared to $7.39 billion a year earlier, according to Benzinga Pro. On Sept. 24, Johnson Controls announced the appointment of Todd Grabowski as vice president and president, Americas. Shares of Johnson Controls fell 1.9% to close at $111.04 on Tuesday. Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables. Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period. JP Morgan analyst Stephen Tusa maintained an Overweight rating and raised the price target from $105 to $125 on Oct. 15, 2025. This analyst has an accuracy rate of 69%. Citigroup analyst Andrew Kaplowitz maintained a Neutral rating and increased the price target from $112 to $119 on Oct. 9, 2025. This analyst has an accuracy rate of 84%. Morgan Stanley analyst Chris Snyder maintained an Overweight rating and increased the price target from $115 to $125 on Aug. 21, 2025. This analyst has an accuracy rate of 77%. RBC Capital analyst Deane Dray maintained a Sector Perform rating and increased the price target from $112 to $114 on July 30, 2025. This analyst has an accuracy rate of 69%. Barclays analyst Julian Mitchell maintained an Equal-Weight rating and raised the price target from $100 to $101 on July 30, 2025. This analyst has an accuracy rate of 73% Considering buying JCI stock? Here’s what analysts think: Read This Next: Top 2 Industrials Stocks You May Want To Dump This Quarter Photo via Shutterstock Market News and Data brought to you by Benzinga APIs © 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
	2025-11-05 08:24 4mo ago	2025-11-05 02:46 4mo ago	Challenger Limited (CFIGY) Shareholder/Analyst Call Transcript	stocknewsapi	CFIGF
Challenger Limited (OTCPK:CFIGY) Shareholder/Analyst Call November 4, 2025 5:30 PM EST Company Participants Mark Chen - General Manager of Investor Relations Nick Hamilton - MD, CEO & Director Alexandra Bell - Chief Financial Officer Anton Kapel - Chief Executive of Insurance Conference Call Participants Freya Kong - BofA Securities, Research Division Kieren Chidgey - UBS Investment Bank, Research Division Siddharth Parameswaran - JPMorgan Chase & Co, Research Division Julian Braganza - Goldman Sachs Group, Inc., Research Division Lafitani Sotiriou - MST Financial Services Pty Limited, Research Division Simon Fitzgerald - Jefferies LLC, Research Division Andrei Stadnik - Morgan Stanley, Research Division Marcus Barnard - Bell Potter Securities Limited, Research Division Presentation Mark Chen General Manager of Investor Relations Good morning, everyone, and welcome to those joining online to Challenger's market briefing on APRA's proposed capital standards for longevity Products. I'm Mark Chen, Challenger's General Manager of Investor Relations. We're coming to you today from our Martin Place head office in Sydney. Before we begin, I would like to acknowledge the Gadigal people of the Eora Nation, the traditional custodians of the land on which we are hosting this event today and pay my respects to both elders, past and present. Today's briefing will be followed by a Q&A session that will only be open to analysts and investors. To ask a question you'll need to have joined via the telephone. As a reminder, today's briefing is based on APRA's proposed capital standards issued last week. We are currently in consultation with APRA with written submissions on these proposed reforms due by 17th of December. As such, there are certain subjects we will be unable to provide responses to, which the teams are working on or that require Challenger Board or APRA approval. These are areas such as target ranges, risk appetite, asset allocation, capital allocation. We will use the session to provide points of clarification of guidance, including the use of illustrative Recommended For You
	2025-11-05 08:24 4mo ago	2025-11-05 02:49 4mo ago	Veris Residential: Shares Have Potential, But Are Fully Priced	stocknewsapi	VRE
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
	2025-11-05 08:24 4mo ago	2025-11-05 02:52 4mo ago	M&S reveals cost of cyber attack as profit almost wiped out	stocknewsapi	MAKSY
The cyber attack on high street department store Marks and Spencer is expected to directly cost roughly £136m. The figure is only the cost of immediate incident systems response and recovery, as well as specialist legal and professional services support. Combined with a loss in sales, as the retailer's online systems were out of action from Easter into the summer, statutory profit before tax at the business has been nearly wiped out for the first half of the year. This profit measure dropped from £391.9m last year to £3.4m this year. About £100m is being claimed back in insurance for the cyberattack, M&S said in its market update. This breaking news story is being updated and more details will be published shortly. Please refresh the page for the latest version. You can receive breaking news alerts on a smartphone or tablet via the Sky News app. You can also follow us on WhatsApp and subscribe to our YouTube channel to keep up with the latest news.
	2025-11-05 08:24 4mo ago	2025-11-05 02:55 4mo ago	Kingman Minerals Prepares for Drilling at High-Grade Mohave Project amid Record Gold Prices	stocknewsapi	KGSSF
November 05, 2025 2:55 AM EST \| Source: Kingman Minerals Ltd. Vancouver, British Columbia--(Newsfile Corp. - November 5, 2025) - Kingman Minerals Ltd. (TSXV: KGS) (OTCQB: KGSSF) (FSE: 47A) ("Kingman" or the "Company") is pleased to update shareholders on the significant progress to date at its flagship Mohave Project in Mohave County, Arizona, which includes the historic Rosebud Mine. Given the current strength in the gold market, Kingman believes the Mohave Project is exceptionally well-positioned for near-term value creation. Historic High-Grade District with Substantial Upside The Mohave Project comprises 72 lode claims (1467 acres or 594 hectares), inclusive of the historic Rosebud Mine. The underground workings include over 2,300 feet of drifts, raises, and crosscuts. Historical (non-NI 43-101) data suggest a potential for up to 664,000 ounces of gold and 2.6 million ounces of silver across multiple parallel vein structures.1 Kingman's focus is to continue to replicate and validate these historic values, then expand and upgrade them according to modern exploration standards. Modern Work Programs & High-Grade Sampling Results Kingman has executed multiple phases of work to date, including two underground reconnaissance programs and two drilling phases, both confirming high-grade gold and silver intercepts at depth. Underground sampling from mineralized veins returned exceptional results, including 688 g/t Au and 468 g/t Ag over 0.18 m, and 252 g/t Au and 341 g/t Ag over 0.46 m. Phase 1 Underground Reconnaissance & Sampling Confirmed access to historic workings and collected high-grade channel and chip samples. A standout result was 252 g/t Au + 341 g/t Ag over 0.46 m on the 100 ft level of the Rosebud Mine.2Phase 2 Underground Reconnaissance & Sampling Expanded sampling efforts on the 100 ft and 200 ft levels, clearing debris to access lower levels, and sending assays to ALS Laboratories (method ME-GRA21).3Key highlights include: SampleLevelWidth (m)Au (g/t) Ag (g/t) RB200-11100 ft, N Stope0.18 m 688 g/t468 g/tRB200-10100 ft, N Stope0.15 m 109 g/t 164 g/t RB200-13100 ft, N Stope0.28 m 70.5 g/t 93 g/t RB200-4 100 ft 0.25 m 2.88 g/t 133 g/t These values confirm the presence of bonanza-grade veins, supporting the historic high grades and underscoring the vertical and lateral continuity potential.3 This combination of strong assay results across multiple locations lays the foundation to validate, expand, and define the resource. With gold prices at or near record levels and many analysts' forecasting further upside, projects with proven high-grade potential in stable jurisdictions are attracting increased investor attention. The Mohave Project's location in Arizona—with good infrastructure and a favorable mining climate—further strengthens its development profile. By converting historic grades into NI 43-101-compliant resources in the near term, Kingman will proceed with extensive exploration work. The high grades seen in both Phase 1 and Phase 2, combined with the modelled continuity from 3D surveys, provide multiple pathways for upside—whether by expanding the known veins, identifying parallel structures, or exploring extensions downward. "We are excited to advance work at Mohave and bring clarity to a district with truly exceptional grade potential," said Simon Studer, Interim CEO of Kingman Minerals Ltd. "Our underground sampling already underscores bonanza-grade zones in multiple places, and the updated mapping and digital modelling give us confidence in targeting these veins for drilling. With gold markets in a strong uptrend, we anticipate drilling to convert this potential into value for our shareholders." TECHNICAL INFORMATION The technical information in this website has been prepared in accordance with the Canadian regulatory requirements set out in National Instrument 43-101 and reviewed on behalf of the company by, Qualified Person: Bradley C. Peek, MSc. CPG Qualified Person for Kingman Minerals Ltd. ABOUT Kingman Minerals Ltd. (TSXV: KGS) is a publicly traded exploration and development company focused on precious metals in North America. The company's flagship project is the fully owned historic Rosebud Mine, located in the Music Mountains, Mohave County, Arizona. High-grade gold and silver veins were discovered in the area in the 1880's and were mined mainly in the late 20's and 30's. Underground development on the Rosebud property included a 400-foot shaft and approximately 2,500 feet of drifts, raises, and crosscuts. The company believes that to explore the full potential of the area, drilling and sampling along strike and depth extensions of existing and additional vein structures is essential. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking information which is not comprised of historical facts. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release includes statements regarding, among other things, the completion transactions completed in the Agreement.Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, regulatory approval processes. Although Kingman believes that the assumptions used in preparing the forward-looking information in this news release are reasonable, including that all necessary regulatory approvals will be obtained in a timely manner, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Kingman disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by applicable securities laws. 1: https://kingmanminerals.com/projects/mohave-project/?utm_source=chatgpt.com "Mohave Project" 2: https://finance.yahoo.com/news/2nd-sampling-program-results-mohave-065500480.html?utm_source=chatgpt.com "2nd Sampling Program Results Mohave Project Mine Shaft ..." 3: https://kingmanminerals.com/projects/mohave-project/2nd-phase-underground-reconnaissance-sampling-program/?utm_source=chatgpt.com "2nd Phase Underground Reconnaissance & Sampling" To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273234
	2025-11-05 08:24 4mo ago	2025-11-05 02:56 4mo ago	The Baldwin Insurance Group, Inc. (BWIN) Q3 2025 Earnings Call Transcript	stocknewsapi	BWIN
Q3: 2025-11-04 Earnings SummaryEPS of $0.31 misses by $0.00 \| Revenue of $365.39M (7.80% Y/Y) beats by $1.69M The Baldwin Insurance Group, Inc. (BWIN) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Bonnie Bishop - Executive Director of Investor Relations Trevor Baldwin - CEO & Non-Independent Director Bradford Hale - Chief Financial Officer Conference Call Participants Charles Peters - Raymond James & Associates, Inc., Research Division Charles Lederer - BMO Capital Markets Equity Research Elyse Greenspan - Wells Fargo Securities, LLC, Research Division Pablo Singzon - JPMorgan Chase & Co, Research Division Andrew Andersen - Jefferies LLC, Research Division Brian Meredith - UBS Investment Bank, Research Division Thomas Mcjoynt-Griffith - Keefe, Bruyette, & Woods, Inc., Research Division Presentation Operator Ladies and gentlemen, greetings, and welcome to the Baldwin Group Third Quarter 2025 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Bonnie Bishop, Executive Director, Investor Relations. Please go ahead. Bonnie Bishop Executive Director of Investor Relations Thank you. Welcome to the Baldwin Group's Third Quarter 2025 Earnings Call. Today's call is being recorded. Third quarter financial results, supplemental information and Form 10-Q were issued earlier this afternoon and are available on the company's website at ir.baldwin.com. Please note that remarks made today may include forward-looking statements subject to various assumptions, risks and uncertainties, including, for example, our strategy with respect to our capital allocation in the future. The company's actual results may differ materially from those contemplated by such statements. For a more detailed discussion, please refer to the note regarding forward-looking statements in the company's earnings release and our most recent Form 10-Q, both of which are available on the Baldwin website. During the call today, the company may also discuss certain non-GAAP financial measures. For a more detailed discussion of these non-GAAP financial measures and historical reconciliation to the most closely comparable GAAP measures, please refer to the Recommended For You
	2025-11-05 08:24 4mo ago	2025-11-05 02:58 4mo ago	Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential	stocknewsapi	MBGPF
, /PRNewswire/ -- Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of MOB-015 (Terclara®) in Europe. The agreement comprises 19 European markets, enabling a coordinated launch across all key EU markets under the leading global antifungal brand Lamisil®. The agreement covers 19 European markets, representing a total population of approximately 500 million people including all major EU countries and the United Kingdom ("Big 5") as well as the eleven countries where Terclara® is already approved but not yet launched. This provides Moberg Pharma the opportunity for a coordinated launch in all key European markets. Karo Healthcare will be responsible for marketing, distribution and sales throughout Europe. Financial terms are not disclosed, but the agreement includes royalties and compensation for delivered products. "We are very pleased to enter this partnership with Karo Healthcare, which has a strong commercial presence across Europe. Launching MOB-015/Terclara® under the well-known Lamisil® brand gives us an exceptional opportunity to establish the product as the market leader also beyond Sweden and Norway," says Anna Ljung, CEO of Moberg Pharma. "Moberg Pharma has developed a unique and clinically well-documented product. Being able to launch MOB-015/Terclara® under the Lamisil® brand is a perfect combination of scientific innovation and commercial strength that gives us a unique position in the market," says Christoffer Lorenzen, CEO of Karo. The Lamisil® brand Terbinafine, originally developed and launched by Novartis under the Lamisil® brand, has long been considered the gold standard treatment for skin and foot fungal infections such as athlete's foot and nail fungus. Lamisil® is present in more than 60 markets worldwide and has become synonymous with its active ingredient, terbinafine, while consistently standing at the forefront of antifungal research and innovation. MOB-015/Terclara®, developed by Moberg Pharma, represents the next generation of terbinafine therapy – a new topical formulation. Oral treatment of nail fungus is associated with risks such as interactions with other medications and liver damage, which are avoided with topical treatment. Previous attempts at topical treatment with terbinafine have failed due to the difficulty of delivering a sufficient amount of the active substance through the nail. MOB-015 is the first topical treatment that has achieved mycological cure on par with oral treatment, with 76% of patients achieving mycological cure in the registration studies. It is therefore particularly satisfying to launch the product under the strong and fitting Lamisil® brand. Launch and regulatory steps Launching MOB-015/Terclara® under the Lamisil® brand, wherever possible, optimizes the product's chances to take a leading position in major European markets. However, the use of the Lamisil® brand for this pharmaceutical product requires approval by the respective national health authorities, which affects the timing of the launch. Both companies intend to initiate launch as soon as possible. The companies will also collaborate to expand current marketing authorizations to additional countries as soon as feasible. For regulatory reasons, markets that are already approved have priority, since new countries cannot be added while a name change or other changes are being implemented. Although the product will be launched under the Lamisil® brand, the connection to Moberg Pharma will be made clear through the marketing concept 'Powered by Terclara®'. A partnership with strong European reach Karo Healthcare is a leading European consumer healthcare company, backed by KKR, a leading global investment firm, and with ambitious growth plans across Europe. With established distribution in all major European pharmacy chains, Karo has the capacity to manage both prescription and over-the-counter products, including prescription-to-nonprescription (Rx-to-OTC) switches. Through this partnership with Karo Healthcare, the product gains broad market coverage and effective distribution right from the outset, which would take Moberg Pharma time to build up on its own. While Moberg Pharma will not launch Terclara® on its own in Europe as part of this collaboration, the company still plans to play an active commercial role in other territories, particularly in the U.S., as part of its long-term strategy. The agreement marks an important milestone in Moberg Pharma's commercial expansion and lays the foundation to establish MOB-015/Terclara® as the new market leader in the treatment of nail fungus across Europe. About this information Moberg Pharma is releasing this information in accordance with the EU's Market Abuse Regulation (MAR). The information was released for public distribution through the contact named below at 8.30 a.m. CET on November 5th, 2025. For additional information, please contact: Anna Ljung, CEO, Phone: +46 8 522 307 01, E-mail: [email protected] This information was brought to you by Cision http://news.cision.com https://news.cision.com/moberg-pharma/r/moberg-pharma-and-karo-healthcare-enter-exclusive-license-agreement-for-mob-015-terclara-in-europe--,c4261942 The following files are available for download: SOURCE Moberg Pharma
	2025-11-05 08:24 4mo ago	2025-11-05 02:58 4mo ago	Marks & Spencer hikes dividend as cyber attack recovery almost complete	stocknewsapi	MAKSY
Marks and Spencer Group PLC (LSE:MKS) reported stronger first-half profits than expected, after the retailer quickly settled its insurance claim at £100 million for the cyber attack that laid it low in the spring. The FTSE 100-listed group generated an adjusted pre-tax profit of £184.1 million in the 26 weeks to 27 September, down from £413.1 million last year as the cyber incident led to some empty shelves as systems were taken offline to thwart attackers. Despite the attack, group sales jumped 22% to £7.97 billion. Food sales, which increased 7.8% and generated an adjusted operating profit of £89.1 million as margins declined to 2.0% from 5.1%. In current trading, margins were said to now be almost back to normal. Fashion, Home & Beauty sales declined 16.4%, but still made a profit from that division at £46.1 million despite margins falling to 2.7% from 12%. The recovery in this arm has been slower, the M&S said, "as systems complexity means it has taken time to smooth the flow of stock". International sales also fell, down 11.6% with profit at £13.3 million, while Ocado Retail posted a £3.1 million operating loss before adjustments. The cyber incident led to £101.6 million in related costs. Reflecting the recovery, the board increased the interim dividend 20% to 1.2p. “The first half of this year was an extraordinary moment in time for M&S,” said chief executive Stuart Machin. “In the second half, we expect profit to be at least in line with last year.” In the fact of the disruption, he hailed further progress on the “Reshape for Growth” strategy, including a £340 million investment in its food supply chain and opening six new stores in the first half. A further 12 are planned before the end of the financial year. Machin added: “Our plan to reshape M&S for long-term sustainable growth is unchanged, our ambitions are undimmed, and our determination to knuckle down and deliver is stronger than ever.”
	2025-11-05 08:24 4mo ago	2025-11-05 02:59 4mo ago	Top Wall Street Forecasters Revamp Humana Expectations Ahead Of Q3 Earnings	stocknewsapi	HUM
Humana Inc. (NYSE:HUM) will release earnings results for the third quarter before the opening bell on Wednesday, Nov. 5. Analysts expect the Louisville, Kentucky-based company to report quarterly earnings at $2.82 per share, down from $4.16 per share in the year-ago period. The consensus estimate for Humana's quarterly revenue is $32.01 billion, compared to $29.4 billion a year earlier, according to Benzinga Pro. On Oct. 28, Humana announced that its board declared a cash dividend to stockholders of 88.5 cents per share. Shares of Humana rose 0.7% to close at $281.87 on Tuesday. Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables. Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period. B of A Securities analyst Kevin Fishbeck maintained a Neutral rating and raised the price target from $280 to $300 on Oct. 10, 2025. This analyst has an accuracy rate of 66%. Mizuho analyst Ann Hynes maintained an Outperform rating and increased the price target from $300 to $345 on Oct. 9, 2025. This analyst has an accuracy rate of 72%. Barclays analyst Andrew Mok maintained an Equal-Weight rating and cur the price target from $315 to $245 on Oct. 3, 2025. This analyst has an accuracy rate of 62%. RBC Capital analyst Ben Hendrix maintained an Outperform rating and increased the price target from $283 to $322 on Aug. 21, 2025. This analyst has an accuracy rate of 62%. Argus Research analyst David Toung reiterated a Hold rating with a price target of $281.99 on Aug. 14, 2025. This analyst has an accuracy rate of 67% Considering buying HUM stock? Here’s what analysts think: Read This Next: Top 2 Industrials Stocks You May Want To Dump This Quarter Photo via Shutterstock Market News and Data brought to you by Benzinga APIs © 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
	2025-11-05 08:24 4mo ago	2025-11-05 03:00 4mo ago	Corero Network Security Builds on Q3 Execution with Major Q4 Wins and Product Breakthroughs	stocknewsapi	DDOSF
Major customer renewal, global expansion, and new innovations position Corero for continued growth into 2026 LONDON , Nov. 5, 2025 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today reported accelerating global growth in Q3 2025, fueled by rising order intake and continued innovation across its SmartWall ONE™ platform, and began Q4 with a major renewal and expansion with a leading US cloud computing provider. Building on strong execution, Corero achieved $7.4 million in Q3 order intake (up from $6.0 million in Q3 2024) with new customer wins spanning the US, UK, Europe, Brazil, and Singapore.
	2025-11-05 08:24 4mo ago	2025-11-05 03:00 4mo ago	Futu to Report Third Quarter 2025 Financial Results on November 18, 2025	stocknewsapi	FUTU
November 05, 2025 03:00 ET \| Source: Futu Holdings Limited HONG KONG, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Futu Holdings Limited (“Futu” or the “Company”) (Nasdaq: FUTU), a leading tech-driven online brokerage and wealth management platform, today announced that it will report its financial results for the third quarter ended September 30, 2025, before U.S. markets open on November 18, 2025. Futu's management will hold an earnings conference call on Tuesday, November 18, 2025, at 7:30 AM U.S. Eastern Time (8:30 PM on the same day, Beijing/Hong Kong Time). Please note that all participants will need to pre-register for the conference call, using the link https://register-conf.media-server.com/register/BI87ab49c568d44b2da54051280cc03405. It will automatically lead to the registration page of "Futu Holdings Ltd Third Quarter 2025 Earnings Conference Call," where details for RSVP are needed. Upon registering, all participants will be provided in confirmation emails with participant dial-in numbers and personal PINs to access the conference call. Please dial in 10 minutes prior to the call start time using the conference access information. Additionally, a live and archived webcast of this conference call will be available at https://ir.futuholdings.com/. About Futu Holdings Limited Futu Holdings Limited (Nasdaq: FUTU) is an advanced technology company transforming the investing experience by offering fully digitalized financial services. Through its proprietary digital platforms, Futubull and moomoo, the Company provides a full range of investment services, including trade execution and clearing, margin financing and securities lending, and wealth management. The Company has embedded social media tools to create a network centered around its users and provide connectivity to users, investors, companies, analysts, media and key opinion leaders. The Company also provides corporate services, including IPO distribution, investor relations and ESOP solution services. Investor Contact Investor Relations Futu Holdings Limited [email protected]
	2025-11-05 08:24 4mo ago	2025-11-05 03:01 4mo ago	Zscaler ThreatLabz Reveals 67% Jump in Android Malware and 40% of IoT Attacks Target Critical Industries and Hybrid Work	stocknewsapi	ZS
Key Findings: Critical infrastructure in the energy sector experienced a 387% increase in attacks compared to the previous yearIndia continues to be the top target for mobile attacks, with 26% of activityThe US remains the top target for IoT attacks, with 54% of activity SAN JOSE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, today published the findings of its Zscaler ThreatLabz 2025 Mobile, IoT, and OT Threat Report, outlining how threat actors are leveraging malware attacks and constantly evolving their tactics. The report uncovered hundreds of malicious apps in the Google Play Store that have been downloaded over 40 million times, targeting users that are searching for productivity and workflow apps. Based on Zscaler's mobile telemetry dataset, the ThreatLabz team identified several emerging mobile threats and new malicious activity, providing valuable insights to help enterprises stay ahead of attackers in a mobile-first world. Hundreds of malicious apps downloaded over 40 million times Similar to last year, this year we again saw threat actors developing and releasing malicious applications targeting trusted marketplaces and hybrid work environments. The result, which the report reveals is a 67% year-over-year increase in Android malware transactions, reflects the continued risks of spyware and banking malware. ThreatLabz researchers identified 239 such applications hosted on the Google Play Store, which were collectively downloaded 42 million times. A key distribution channel for this malware was the "Tools" category, disguising malicious applications as productivity and workflow tools. This tactic capitalizes on users' trust in functionality-driven applications–a trust that is particularly strong in hybrid and remote work settings where mobile devices are integral to professional tasks. Manufacturing remains a top target for mobile and IoT attacks ThreatLabz's analysis of Android attack volumes reveals that the Manufacturing and Energy sectors remain prime targets for cybercriminals due to the potential for significant returns. Notably, the energy sector experienced a substantial 387% increase in attacks compared to the previous year, highlighting an escalating threat to critical infrastructure and greater exploitation of vulnerabilities within these essential industries. In the IoT landscape, the Manufacturing and Transportation sectors continue to be the most frequently targeted verticals. This year, each sector accounted for 20.2% of all observed IoT malware attacks, collectively representing over 40% of total incidents. This marks a shift from 2024, when Manufacturing alone represented 36% of total incidents, followed by Transportation at 14%. This suggests that while Manufacturing remains a critical target, threat actors are increasingly diversifying their efforts across other high-dependency IoT industries. Most prevalent IoT malware Roughly 40% of blocked transactions are linked to the Mirai family alone, and Mozi has overtaken Gafgyt as the second highest malware family. Together, Mirai, Mozi, and Gafgyt account for roughly 75% of all malicious payloads in IoT environments. Mobile attacks cluster in India, US and Canada; US is the IoT threat epicenter at 54 percent Worldwide, mobile threats have surged, with many of these attacks concentrated in three key regions: India, accounting for 26% of all mobile attacks, the United States at 15%, and Canada at 14%. India, in particular, experienced a significant 38% increase in mobile threat attacks compared to the previous year. The top five countries that receive the most mobile malware traffic are: India (26%)United States (15%)Canada (14%)Mexico (5%)South Africa (4%) The report also revealed that the US is both a hub for IoT activity (54.1%) and a primary target for malware attacks. The top five countries that receive the most IoT malware traffic are: United States (54%)Hong Kong (15.%)Germany (6%)India (5%)China (4%) “Attackers are pivoting to areas with maximum impact. We’re seeing a YoY rise of 67% in malware targeting mobile devices and 387% in IoT/OT attacks on energy sectors often hosting critical infrastructure, which is a massive swing,” said Deepen Desai, EVP and Chief Security Officer at Zscaler. “A Zero Trust everywhere approach, combined with AI-powered threat detection, is imperative to reducing the attack surface, limit lateral movement, and provide organizations the defense they need against ever-evolving attacks.” Additional highlights and new findings this year A new backdoor called Android Void malware has infected 1.6 million Android-based TV boxes, primarily in India and BrazilNew Remote Access Trojan (RAT), Xnotice, was identified for targeting job seekers in the oil and gas industry, particularly in MENAAdware overtook the Joker malware family as the top mobile threat, with a leading 69% of cases, while Joker dropped to 23% of cases, from 38% last yearThreat actors are abandoning card-focused fraud in favor of mobile payments Defending against growing IoT, OT and Mobile threats Zscaler Zero Trust Branch delivers comprehensive security and operational efficiency for branch offices, remote sites, and distributed networks, designed for environments that rely heavily on mobile, IoT, cellular IoT, and OT technologies. Using a cloud-native and AI-driven Zero Trust architecture, Zscaler aims to ensure all users, devices, and applications are safeguarded with continuous real-time verification and robust policy enforcement, regardless of their location relative to the traditional network perimeter. Zscaler Cellular offers secure, scalable, and efficient connectivity as a service for IoT and mobile devices that rely on cellular connections. This solution, powered by the Zscaler Zero Trust Exchange™ platform, addresses the growing security challenges posed by billions of IoT devices and mobile endpoints, which traditional security methods often fail to secure effectively. It achieves this by enforcing granular policies, providing centralized visibility, and eliminating attack surfaces for all cellular traffic. Download your copy The 2025 Mobile, IoT, and OT Threat Report highlights the critical importance of securing mobile endpoints, IoT devices, and OT systems. Access the full report at https://www.zscaler.com/campaign/threatlabz-mobile-iot-ot-report. Research Methodology Mobile The research methodology for this report includes analysis of mobile transactions and associated cyberthreats based on data collected from the Zscaler cloud between June 2024 and May 2025. The dataset comprises more than 20 million threat-related mobile transactions. IoT/OT The team focused their research on understanding the distinct attributes and activity of IoT devices via device fingerprinting (DFP) and analyzing the IoT malware threat landscape. Device fingerprinting data from March 2025 to May 2025 included: A complete inventory of devices, including device types and manufacturersThe volume and source of IoT device transactionsThe industries and geographies contributing to IoT traffic IoT malware threat data from June 2024 to May 2025 included: The most active malware familiesThe industries and geographies most targeted by IoT attacksThe top attacked devices About Zscaler Zscaler (NASDAQ: ZS) accelerates digital transformation so customers can be more agile, efficient, resilient, and secure. The Zscaler Zero Trust Exchange™ platform protects thousands of customers from cyberattacks and data loss by securely connecting users, devices, and applications in any location. Distributed across more than 160 data centers globally, the SASE-based Zero Trust Exchange is the world’s largest in-line cloud security platform. Media Contact Taylor Dunton, Senior Director, Public Relations, [email protected] A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a9909238-c36f-4286-a7b6-5916db8e5847 Threatlabz 2025 Mobile, IoT, and OT Threat Report 2025 Threatlabz Mobile, IoT, and OT Threat Report-
	2025-11-05 08:24 4mo ago	2025-11-05 03:05 4mo ago	Point and Funds Managed by Blue Owl Capital Close Oversubscribed $390 Million Home Equity Investment Rated Securitization	stocknewsapi	OWL
Palo Alto, California, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Point, the leading home equity investment platform making homeownership more valuable and accessible, and funds managed by Blue Owl Capital (“Blue Owl”) announced today that they have completed a rated securitization of Point’s Home Equity Investment (“HEI”) assets, issuing $390 million of rated asset-backed securities (the “Transaction”), marking Point’s third securitization of 2025 and continuing the firm’s record of programmatic issuance. The Transaction closed on October 28th, 2025. The issuer, Point Securitization Trust 2025-2, issued $254.2 million of senior class A-1 securities rated A (low) (sf), $46.6 million of mezzanine class A-2 securities rated BBB (low) (sf), $45.9 million of subordinate class B-1 securities rated BB (low) (sf), and $43.3 million of subordinate class B-2 securities rated B (high) (sf) (retained), all rated by Morningstar DBRS. A portion of the notes was acquired by accounts managed by an affiliate of Blue Owl. The Transaction attracted 29 unique investors, including eight new entrants to the Point securitization platform, resulting in over $1.6 billion in orders, and underscoring the continued institutional interest and confidence in Point’s program. Co-sponsoring the Transaction with a subsidiary of Blue Owl, Point was the originator of all the HEIs in the securitization and will continue to service the assets. In addition to complying with U.S. credit risk retention rules, the Transaction is the first HEI securitization to include undertakings related to both the EU Securitization Regulation and the UK Securitization Framework, as well as the transparency requirements of the EU Securitization Regulation. These steps further position Point’s securitization platform to meet the standards of European and UK institutional investors, reflecting Point’s commitment to broadening global access to the HEI market. “Building on the strong momentum of PNT 25-1, this transaction reflects growing confidence in home equity investments as a mainstream asset class,” said Eddie Lim, co-founder and CEO of Point. “As homeowners and investors continue to seek flexible, sustainable ways to unlock and deploy capital, Point is proud to lead with consistency, transparency, and execution.” Since pioneering the HEI category in 2015, Point has closed six securitizations and continues to set benchmarks for liquidity, scalability, and transparency in alternative home equity financing. “This marks the third transaction that Blue Owl has co-sponsored alongside Point. We were able to combine legacy seasoned collateral we acquired earlier this year with new originations purchased directly from Point to issue the largest public HEI securitization to date,” said Ivan Zinn, Head of Alternative Credit at Blue Owl. “Blue Owl and Point have a longstanding relationship dating back to 2018, and we are excited to continue working with the Point team.” Barclays Capital Inc. (“Barclays”) was the sole-structuring agent for the issuance. Barclays, Nomura Securities International Inc., and Cantor Fitzgerald & Co. were joint bookrunners on the Transaction, and East West Markets, LLC and StoneX Financial Inc. were co-managers on the Transaction. About Point Point is the leading home equity platform making homeownership more valuable and accessible. Point’s flagship product, the Home Equity Investment (HEI), empowers homeowners to unlock their equity to eliminate debt, get through periods of financial hardship, and diversify their wealth – without adding to their monthly expenses. Point has worked with more than 15,000 homeowners, unlocking more than $1.5 billion in home equity. Point’s HEI enables investors to access a previously untapped asset class – owner-occupied residential real estate. Founded in 2015 by Eddie Lim, Eoin Matthews, and Alex Rampell, Point is backed by top investors, including Westcap, Andreessen Horowitz, Ribbit Capital, Greylock Partners, Bloomberg Beta, Blue Owl Capital, Alpaca VC, and Prudential. The company is headquartered in Palo Alto, CA. For more information, please visit www.point.com About Blue Owl Blue Owl (NYSE: OWL) is a leading asset manager that is redefining alternatives®. With over $295 billion in assets under management as of September 30, 2025, we invest across three multi-strategy platforms: Credit, Real Assets and GP Strategic Capital. Anchored by a strong permanent capital base, we provide businesses with private capital solutions to drive long-term growth and offer institutional investors, individual investors, and insurance companies differentiated alternative investment opportunities that aim to deliver strong performance, risk-adjusted returns, and capital preservation. Together with over 1,365 experienced professionals globally, Blue Owl brings the vision and discipline to create the exceptional. To learn more, visit www.blueowl.com.
	2025-11-05 08:24 4mo ago	2025-11-05 03:13 4mo ago	Marks & Spencer Profits Plummet on Cyberattack	stocknewsapi	MAKSY
Adjusted pretax profit plunged 55%, but the retailer said it expects a recovery in the second half of its fiscal year.
	2025-11-05 08:24 4mo ago	2025-11-05 03:14 4mo ago	ONEOK: Get Ready For A Stronger Rally	stocknewsapi	OKE
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
	2025-11-05 08:24 4mo ago	2025-11-05 03:15 4mo ago	E3 Lithium to Host Webinar on November 5, 2025 @ 9:00AM MT	stocknewsapi	EEMMF
CALGARY, Alberta--(BUSINESS WIRE)--E3 LITHIUM LTD. (TSXV: ETL) (FSE: OW3) (OTCQX: EEMMF), (“E3 Lithium” or the “Company”) a leader in Canadian lithium development, reminds shareholders and interested stakeholders the Company is hosting a Webinar this morning, November 5, 2025, at 9:00am MT. During the presentation, Chris Doornbos, President and CEO, and members of the E3 Lithium management team will discuss: Summary of Phase 1 Demonstration Facility achievements Update on Phase 2 Demonstration Facility progress Review of the recently closed equity financing Positioning of E3 Lithium within the North American critical minerals strategy Recent federal and provincial government initiatives supporting lithium development Upcoming milestones for the Clearwater Project for Q4 2025 and 2026 Webinar Details: Date: Wednesday, November 5, 2025 Time: 09:00 AM Mountain Time (11:00 AM Eastern Time) Registration Link: Zoom (click here to log in at the time of the webinar; no need to register in advance) Duration: 45 minutes presentation + 15 minutes Q&A If you are having issues with the registration link, copy this address into your browser to be directed to the log in page: https://us02web.zoom.us/webinar/register/WN_o022pANsTUSsiD6uPUdTag The webinar will be followed by a live Q&A session where attendees can submit questions in real-time. Participants are encouraged to submit questions in advance by emailing [email protected] to ensure they are reviewed during the webinar. The webinar recording will be made available on the Company's website following the event. ON BEHALF OF THE BOARD OF DIRECTORS Chris Doornbos, President, CEO & Chair E3 Lithium Ltd. About E3 Lithium E3 Lithium is a development company with a total of 21.2 million tonnes (Mt) of lithium carbonate equivalent (LCE) Measured and Indicated1 resources as well as 0.3 Mt LCE Inferred mineral resources2 in Alberta and 2.5 Mt LCE Inferred mineral resources3 in Saskatchewan. The Clearwater Project Pre-Feasibility Study outlined a 1.13 Mt LCE proven and probable mineral reserve with a pre-tax NPV(8%) of USD 5.2 Billion with a 29.2% IRR and an after-tax NPV(8%) of USD 3.7 Billion with a 24.6% IRR1. 1: The Clearwater Project NI 43-101 Pre-Feasibility Study, effective June 20, 2024 (the “PFS”), identified 16.2 Mt LCE (measured and indicated) and is available on the E3 Lithium website (www.e3lithium.ca/technical-reports/) and SEDAR+ (www.sedarplus.ca). 2: The mineral resource NI 43-101 Technical Report for the Garrington District Lithium Resource Estimate, effective June 25, 2025, identified 5.0 Mt LCE (measured and indicated) and 0.3 Mt LCE (inferred) and is available on the E3 Lithium website (www.e3lithium.ca/technical-reports/) and SEDAR+ (www.sedarplus.ca). 3: The mineral resource NI 43-101 Technical Report for the Estevan Lithium District, effective May 23, 2024, identified 2.5 Mt LCE (inferred) and is available on the E3 Lithium website (www.e3lithium.ca/technical-reports/) and SEDAR+ (www.sedarplus.ca). Unless otherwise indicated, Kevin Carroll, P. Eng., Chief Development Officer and a Qualified Person under National Instrument 43-101, has reviewed and is responsible for the technical information contained on this news release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions or forward-looking information within the meaning of applicable securities laws. Forward-looking statements are frequently identified by such words as “believe”, “may”, “will”, “plan”, “expect”, “anticipate”, “estimate”, “intend”, “project”, “potential”, “possible” and similar words referring to future events and results. Forward-looking statements are based on the current opinions, expectations, estimates and assumptions of management in light of its experience, and perception of historical trends, but such statements are not guarantees of future performance. All forward-looking information (including future-orientated financial information) is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of mineral exploration and development, fluctuating commodity prices, the effectiveness and feasibility of emerging lithium extraction technologies which have not yet been tested or proven on a commercial scale or on the Company’s brine, risks related to the availability of financing on commercially reasonable terms and the expected use of proceeds; operations and contractual obligations; changes in estimated mineral reserves or mineral resources; future prices of lithium and other metals; availability of third party contractors; availability of equipment; failure of equipment to operate as anticipated; accidents, effects of weather and other natural phenomena and other risks associated with the mineral exploration industry; the Company’s lack of operating revenues; currency fluctuations; risks related to dependence on key personnel; estimates used in financial statements proving to be incorrect; competitive risks and the availability of financing, as described in more detail in our recent securities filings available under the Company’s profile on SEDAR+ (www.sedarplus.ca). Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law. More News From E3 LITHIUM LTD.
	2025-11-05 08:24 4mo ago	2025-11-05 03:16 4mo ago	Paylocity Holding Corporation (PCTY) Q1 2026 Earnings Call Transcript	stocknewsapi	PCTY
Q1: 2025-11-04 Earnings SummaryEPS of $1.75 beats by $0.18 \| Revenue of $408.17M (12.46% Y/Y) beats by $8.64M Paylocity Holding Corporation (PCTY) Q1 2026 Earnings Call November 4, 2025 5:00 PM EST Company Participants Ryan Glenn - Chief Financial Officer Steven Beauchamp - Executive Chairman of the Board Toby Williams - President, CEO & Director Conference Call Participants Brad Reback - Stifel, Nicolaus & Company, Incorporated, Research Division Mark Marcon - Robert W. Baird & Co. Incorporated, Research Division Daniel Jester - BMO Capital Markets Equity Research Connor Passarella Sitikantha Panigrahi - Mizuho Securities USA LLC, Research Division Sheldon McMeans - Barclays Bank PLC, Research Division Jared Levine - TD Cowen, Research Division Jacob Roberge - William Blair & Company L.L.C., Research Division Ian Black Jordan Boretz Jessica Wang - Raymond James & Associates, Inc., Research Division Kincaid LaCorte Aleksandr Zukin - Wolfe Research, LLC Matthew VanVliet - Cantor Fitzgerald & Co., Research Division Jason Celino - KeyBanc Capital Markets Inc., Research Division George Michael Kurosawa - Citigroup Inc., Research Division Zachary Gunn - Financial Technology Partners LP Madeline Brooks Jacob Cody Smith - Guggenheim Securities, LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Paylocity Holding Corporation First Quarter 2026 Fiscal Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Ryan Glenn, Chief Financial Officer. Please go ahead. Ryan Glenn Chief Financial Officer Good afternoon, and welcome to Paylocity's earnings results call for the first quarter of fiscal '26, which ended on September 30, 2025. I'm Ryan Glenn, Chief Financial Officer. And joining me on the call today are Steve Beauchamp, Executive Chairman; and Toby Williams, President and CEO of Paylocity. Today, we will be discussing the results announced in our press release issued after the market closed. A webcast replay of this call will be available for the next 45 days on our website under the Investor Relations tab. Recommended For You
	2025-11-05 08:24 4mo ago	2025-11-05 03:16 4mo ago	AGC Inc. (ASGLY) Q3 2025 Earnings Call Transcript	stocknewsapi	ASGLY
AGC Inc. (OTCPK:ASGLY) Q3 2025 Earnings Call November 5, 2025 1:00 AM EST Company Participants Kazumi Tamaki - Executive Officer and GM of Corporate Communications & Investor Relations Shinji Miyaji - Senior EVP, CFO, CCO & Director Presentation Kazumi Tamaki Executive Officer and GM of Corporate Communications & Investor Relations Let us get started. Welcome to the earnings briefing of AGC Inc. for the third quarter of fiscal year 2025. I'm Kazumi Tamaki, General Manager, Corporate Communications and Investor Relations, serving as moderator. Today's attendees are Shinji Miyaji, Executive Vice President, Executive Officer and CFO; and Tomoyuki Shiokawa, Executive Officer, General Manager of Finance and Control Division. We will first have CFO Miyaji, provide an overview of the financial results for the third quarter, followed by a Q&A session. We are planning to finish at 3:45 p.m. Your cooperation is appreciated. Without further ado, I ask CFO, Miyaji, to start his presentation. Shinji Miyaji Senior EVP, CFO, CCO & Director Thank you. This is Shinji Miyaji, the CFO. Please turn to Page 3. The highlights. Net sales for the first 9 months totaled JPY 1,512.1 billion, down JPY 22.1 billion year-on-year. Positives included an improved product mix and pricing policies for automotive glass, increased shipments and pricing policies for Performance Chemicals and pricing policies for architectural glass in Europe and the Americas, while negatives included a PVC price decline, decreased shipments of EUV photo blanks and European architectural glass and the impact of last year's Russian business transfer. Operating profit was JPY 94.8 billion, up JPY 0.8 billion on effects of profit improvement measures in displays and others despite the adverse impact of the aforementioned factors as well as higher raw materials and fuel costs. Net income attributable to the owners of the parent was up JPY 145.9 billion at JPY 39.5 billion Recommended For You
	2025-11-05 08:24 4mo ago	2025-11-05 03:17 4mo ago	Google's $32 billion deal for Wiz clears DOJ antitrust review, Wiz CEO tells WSJ	stocknewsapi	GOOG GOOGL
The Google logo is pictured at the entrance to the Google offices in London, Britain January 18, 2019. REUTERS/Hannah McKay Purchase Licensing Rights, opens new tab Nov 5 (Reuters) - Cybersecurity company Wiz has cleared a U.S. Justice Department (DOJ) antitrust review of its acquisition by Google-parent Alphabet (GOOGL.O), opens new tab, Wiz CEO said in a Wall Street Journal event on Tuesday. The deal, valued at about $32 billion, would be Alphabet's largest acquisition. It will integrate Wiz into Google's cloud unit, enhancing the company's cybersecurity solutions to help businesses mitigate critical risks. Sign up here. "Definitely, this is an important milestone, but we’re still in the journey between signing and closing," Wiz CEO Assaf Rappaport said, when asked about the DOJ review of the deal. In June, Bloomberg had reported that the DOJ antitrust enforcers were reviewing whether Alphabet's planned acquisition the cybersecurity firm would illegally limit competition in the marketplace. "We look forward to completing the review process in other jurisdictions. The acquisition of Wiz is expected to close in 2026, subject to customary closing conditions," a Google spokesperson told Reuters in an emailed statement. The DOJ and Wiz did not immediately respond to Reuters requests for comment. Reporting by Abu Sultan and Devika Nair in Bengaluru, Editing by Eileen Soreng Our Standards: The Thomson Reuters Trust Principles., opens new tab
	2025-11-05 08:24 4mo ago	2025-11-05 03:21 4mo ago	Marks & Spencer steadies the ship after cyber attack. But questions linger over recovery pace	stocknewsapi	MAKSY
Marks and Spencer Group PLC (LSE:MKS) shares slipped about 3% in early trading despite results that analysts described as “better than feared,” following a turbulent six months dominated by a major cyber attack that knocked its online operations offline for 46 days. The retailer reported adjusted pre-tax profit of £184 million for the first half of its financial year, a sharp fall from £413 million a year ago but comfortably ahead of analysts’ forecasts of around £76 million. That figure was boosted by a prompt £100 million insurance payout covering losses from the cyber incident in April, which crippled the group’s website and led to weeks of restricted trading. Even so, the results underline how far M&S has come since its near-collapse a decade ago. Shore Capital, which acts as house broker, said weaker businesses “would not have emerged as robust as M&S to the malevolent challenges” it faced this year. The company expects to be back to full operational strength by the end of the current financial year, with its food division already close to pre-attack performance levels. Chief executive Stuart Machin said the group had “so much more to do and so much opportunity ahead,” but the immediate focus remains on restoring momentum in its fashion and home arm, which was hit hardest when online trading stopped. Food sales rose 7.8% in the half-year, helped by more shoppers and new product launches, though margins were squeezed by markdowns and waste. By contrast, fashion, home and beauty sales fell 16% after online orders plunged 42%. The division’s operating profit tumbled to £46 million from £243 million a year earlier. ShoreCap expects full-year adjusted pre-tax profit of £655 million, including the insurance settlement, and at least flat profit growth in the second half compared with last year’s £468 million. Underlying profit, excluding the payout, is forecast at £555 million. The company raised its interim dividend by 20% to 1.2p a share, a move analysts said demonstrated management’s confidence in cash flow. Net cash stood at £176 million, although total debt, including leases, increased slightly to £2.5 billion. Despite the disruption, M&S is pushing ahead with its store renewal programme. Fifteen shops opened in the first half, with another 20 planned by year-end, including two new full-line outlets in Bath and Bristol. Investment in logistics and technology is also continuing, including a £340 million food distribution centre in Daventry set to open in 2029. Still, the road ahead looks far from certain. ShoreCap trimmed its 2027 profit forecast by 2.5% amid fears of higher taxes and softer consumer demand after Chancellor Rachel Reeves’ warning that “we are all in this together". This is seen as a prelude to a Tresury raid on earnings. M&S shares, at about 374p (down 10.5p), trade on roughly 11 times expected 2027 earnings, a discount to Next and Tesco. Analysts argue that ongoing progress could narrow that gap. For now, today’s dip in the share price suggests investors are reserving judgment. M&S may have weathered the cyber storm better than expected, but the next few months will show whether it can fully reclaim the digital momentum it worked so hard to build.
	2025-11-05 07:24 4mo ago	2025-11-05 01:46 4mo ago	Soleno Therapeutics, Inc. (SLNO) Q3 2025 Earnings Call Transcript	stocknewsapi	SLNO
Soleno Therapeutics, Inc. (SLNO) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Anish Bhatnagar - Chairman, President, CEO & COO Meredith Manning - Chief Commercial Officer James MacKaness - CFO & Compliance Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Tyler Van Buren - TD Cowen, Research Division Moritz Reiterer - Guggenheim Securities, LLC, Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Yale Jen - Laidlaw & Company (UK) Ltd., Research Division Katherine Dellorusso Jade Montgomery Presentation Operator Good afternoon, and thank you for standing by. Welcome to Soleno Therapeutics Third Quarter 2025 Financial and Operating Results Conference Call and webcast. [Operator Instructions]. As a reminder, today's webcast is being recorded. I would now like to introduce Brian Ritchie of LifeSci Advisors. Please go ahead. Brian Ritchie Lifesci Advisors, LLC Thank you. Good afternoon, everyone, and thank you for joining us to discuss Soleno Therapeutics Third Quarter 2025 financial and operating results. Please note, we will be making certain forward-looking statements today. We refer you to Soleno's SEC filings for a discussion of the risks that may cause actual results to differ from the forward-looking statements. On the call with me today for Soleno are Anish Bhatnagar, Soleno's Chairman and Chief Executive Officer; Meredith Manning, Soleno's Chief Commercial Officer; and Jim MacKaness, Soleno's Chief Financial Officer. With that, I will now turn the call over to Anish. Anish Bhatnagar Chairman, President, CEO & COO Thank you, Brian, and thank you, everyone, for joining us for our third quarter results call Recommended For You
	2025-11-05 07:24 4mo ago	2025-11-05 01:47 4mo ago	Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount	stocknewsapi	NVO
Danish pharmaceutical giant Novo Nordisk said Wednesday it is lowering its growth expectations for its key obesity and diabetes treatments. Net profit for the quarter came in at 20 billion Danish kroner ($3.1 billion) in line with the 20.12 billion Danish kroner anticipated by analysts in a FactSet poll. Diabetes and obesity care were a key growth driver following the uptake of Wegovy and Ozempic, however the company lowered its expectations for growth, citing prescription trends, competition and pricing pressure. Sales of its blockbuster weight loss drug Wegovy rose 18% year-on-year to hit 20.35 billion Danish kroner in the three months to September, slightly below the 21.35 billion kroner expected by analysts. watch now Novo's Copenhagen-listed shares have tumbled more than 50% over the course of this year, as a slew of headwinds has shaken investor confidence in what was once Europe's most valuable firm. Stock Chart IconStock chart icon Novo Nordisk share price Alongside a series of disappointing trial results, increasing competition in the obesity drug space and challenges arising from U.S. policies on drug pricing and tariffs, Novo has been contending with leadership shakeups and pushback against a key acquisition. Analysts, as a result, have been mixed on the stock. Jefferies recently cut its rating to underperform while Berenberg is positive on the stock, saying Novo has hit "peak uncertainty." "Novo's superior growth profile and best-in-class R&D returns warrants a higher valuation premium to its peers," the bank said. Metsera bidNovo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from U.S. pharma giant Pfizer. On Monday, Pfizer said it had filed a second lawsuit against Novo and Metsera, arguing that Novo's bid for the smaller company was anticompetitive. A spokesperson for Novo said in a statement that Pfizer's allegations were "false and without merit." Novo then ramped up its bid for Metsera on Tuesday, saying it was now offering up to $10 billion compared to the earlier offer of around $9 billion. "Novo Nordisk believes that the proposal, including the structure of the transaction, complies with all applicable laws and is in the best interest of patients who will benefit from our commitment to innovation, as well as Metsera's shareholders," the company said in a statement, noting that the deal was also subject to the term's of Pfizer's merger agreement with Metsera. Metsera said on Tuesday that the revised offer was "superior" to a revised bid made by Pfizer.
	2025-11-05 07:24 4mo ago	2025-11-05 01:48 4mo ago	Siemens Healthineers Reports Fall in Profits, Citing Tariffs	stocknewsapi	SMMNY
Higher comparable revenue stemming from the transformation program of its diagnostics business was offset by a hit from U.S. tariffs.

Saved

Published

Title

Source

Tickers

2025-11-05 09:24 4mo ago

2025-11-05 03:51 4mo ago

Novo Nordisk accepts Ozempic, Wegovy and Rybelsus prices in US Medicare negotiations

stocknewsapi

NVO

A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. REUTERS/Tom Little/File Photo Purchase Licensing Rights, opens new tab

CompaniesLONDON, Nov 5 (Reuters) - Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes and obesity medicines Ozempic, Wegovy and Rybelsus, which will become effective in January 2027.

Novo made the disclosure in its quarterly earnings report.

Sign up here.

The price negotiation process was established under President Biden's signature IRA in 2022.

Novo's drugs are among 15 selected as the second group of medications undergoing the process, and are among the most expensive for the Medicare health program for people aged 65 and older or with disabilities.

Reporting by Maggie Fick; Editing by Jan Harvey

Our Standards: The Thomson Reuters Trust Principles., opens new tab

2025-11-05 09:24 4mo ago

2025-11-05 03:52 4mo ago

AI Sales May Soar 600% by 2028: 2 Brilliant AI Stocks to Buy Now, According to Wall Street

stocknewsapi

DDOG GOOG GOOGL

Explosive growth in artificial intelligence spending creates an opportunity for patient investors.

Capital spending related to artificial intelligence (AI) added more than a percentage point to U.S. economic growth during the first half of 2025, surpassing consumer spending as the primary source of expansion. But Evercore analyst Julian Emanuel says the bull market is far from over, calling AI the most transformative technology since the internet.

Indeed, Morgan Stanley analysts estimate AI sales across cloud and software companies will grow more than 600% to surpass $1 trillion annually by 2028. Investors can lean into that trend by purchasing shares of Alphabet (GOOGL 2.18%) (GOOG 2.13%) and Datadog (DDOG 2.82%).

Analysts are generally bullish on both stocks:

Among 73 analysts, Alphabet has a median target price of $330 per share. That implies 19% upside from its current share price of $278.

Among 46 analysts, Datadog has a median target price of $170 per share. That implies 10% upside from its current share price of $155.

Read on to learn about these AI stocks.

Image source: Getty Images.

1. Alphabet
Alphabet is the largest adtech company in the world due to its ability to engage internet users and source consumer data through platforms like Google Search and YouTube. The search market is undoubtedly shifting toward artificial intelligence (AI) tools like Perplexity and ChatGPT, but Alphabet is leaning into the trend with its own generative AI overviews.

Alphabet's Google also runs the third-largest public cloud in terms of cloud infrastructure and platform services (CIPS). The company accounted for 13% of CIPS revenue in the third quarter, up a percentage point from where it started the year. As a recognized leader in AI infrastructure and large language models, Google is well positioned to continue gaining share as AI demand increases.

Alphabet recently reported solid third-quarter financial results that beat estimates on the top and bottom lines. Revenue increased 16% to $102 billion, an acceleration from 15% growth in the same period last year, and generally accepted accounting principles (GAAP) earnings increased 35% to $2.87 per diluted share. CFO Anat Ashkenazi highlighted strong demand for AI infrastructure, specifically calling attention to interest in custom chips and Gemini models.

Wall Street estimates Alphabet's earnings will increase at 15% annually over the next three years. That makes the current valuation of 27 times earnings look reasonable. Investors should feel comfortable buying a small position in this AI stock today.

Today's Change

(

-2.18

%) $

-6.18

Current Price

$

277.54

2. Datadog
Datadog develops observability software. Its platform includes about two dozen products that help businesses monitor the performance of critical IT infrastructure and applications. It also features an artificial intelligence engine called Watchdog that automates anomaly detection, incident alerts, and root cause analysis to help operations teams resolve problems more quickly.

The artificial intelligence revolution should be a tailwind for Datadog. Forrester Research recently recognized the company as a leader in AI for IT operations, a technology that leans on automation to help IT teams keep enterprise software and services functional. Gartner has also recognized the company as a leader in observability platforms, citing its ability to support generative AI workloads.

Datadog reported encouraging second-quarter financial results that beat estimates on the top and bottom lines. Revenue rose 28% to $827 million, and non-GAAP earnings increased 7% to $0.46 per diluted share. CEO Olivier Pomel highlighted momentum with new AI agents that automate incident response, coding, and security event triage.

Wall Street estimates Datadog's adjusted earnings will grow at 19% annually through 2028. That makes the current valuation of 84 times earnings look expensive. But I think analysts have missed the mark.

Datadog beat the consensus earnings estimate by an average of 15% over the last six quarters. That pattern is likely to continue as the company focuses on cost savings and gradually pulls back on R&D spending.

Investors with a time horizon of at least three years to five years should feel comfortable buying a small position today. If the stock price drops 15%-plus at some point in the future, consider building a slightly larger position.

Trevor Jennewine has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Datadog, and Evercore. The Motley Fool recommends Gartner. The Motley Fool has a disclosure policy.

2025-11-05 09:24 4mo ago

2025-11-05 03:54 4mo ago

Municipal Bonds: I'm Choosing HYMB Over HYD

stocknewsapi

HYD HYMB

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

2025-11-05 09:24 4mo ago

2025-11-05 03:55 4mo ago

Michael Burry of "The Big Short" Fame and Warren Buffett Have Piled Into This Dirt Cheap but Troubled Stock. Should You Follow?

stocknewsapi

UNH

This company's recovery story is picking up momentum.

Before buying or selling a stock, it's important to consider your own investment style instead of following the crowd. But this doesn't mean you shouldn't look around at what others are doing -- especially if they are investors who have proven their abilities over time. You won't follow their every move, but certain ones could offer you inspiration.

Two such investors are Michael Burry and Warren Buffett. Burry took the spotlight when he bet against the U.S. housing market prior to the subprime crash -- and made more than $700 million for clients of his hedge fund. The story was brought to the silver screen in the movie The Big Short a few years ago. As for Buffett, he's been wowing the market for nearly 60 years. Over that time period, at the head of Berkshire Hathaway, the billionaire has delivered market-beating returns -- and his words of wisdom have guided investors through any market environment.

Burry could be seen as more of an aggressive investor, while Buffett as more cautious, but these two market stars have one thing in common. They don't follow the crowd. And in recent times, that's led them both to invest in a dirt cheap but troubled stock. Now, the question is: Should you follow their lead? Let's find out.

Image source: Getty Images.

A leader in its industry
The company Burry and Buffett have invested in is one that's a leader in its industry but has suffered a few setbacks over the past year. I'm talking about UnitedHealth Group (UNH 0.89%). The biggest U.S. health insurer reported disappointing earnings in the first two quarters of this year, unexpectedly lost its chief executive officer, and faced a Department of Justice probe into its Medicare billing processes.

Still, in the second quarter of the year, Burry and Buffett opened positions in UnitedHealth. Burry purchased 20,000 shares and also bought 350,000 in call options -- this type of option, allowing the investor to buy the stock at a certain price before a set time, is a bet that the stock price will rise. Buffett bought 5,039,564 UnitedHealth shares in the quarter.

Today's Change

(

-0.89

%) $

-2.96

Current Price

$

330.83

UnitedHealth saw its valuation drop during that three-month period, so it's possible these investing experts bought shares at an interesting price.

UNH PE Ratio (Forward) data by YCharts

And, today, trading at 20x forward earnings estimates, the stock could be considered dirt cheap -- if we're optimistic about the company recovering from current troubles and returning to growth.

Identifying problems and taking action
So now the question is: Should we be optimistic about the UnitedHealth recovery story and follow Burry and Buffett into the stock? Though it will take some time for UnitedHealth to turn things around, the good news is the company has spotted the problems, is addressing them, and already is making progress. UnitedHealth said earnings weakness mainly has been due to mispricing and market positioning -- the positive point here is these are two elements the company can control.

In the recent earnings report, UnitedHealth said repricing within the insurance business -- UnitedHealthcare -- should drive operating earnings growth next year. The company says its efforts to boost the Optum business -- which provides services such as pharmacy care -- will show results next year and thereafter. For example, in Optum Health, the company aims to narrow the provider network, which had grown too wide.

Raising 2025 guidance
As a result of UnitedHealth's recent moves, the company reported double-digit revenue growth to more than $113 billion and net income that surpassed analysts' estimates. The company also lifted its 2025 guidance to at least $14.90 per share. That's up from an earlier forecast of $14.65 per share.

UnitedHealth is showing that it's on the right path to recovery and growth, and at the same time, the stock is very reasonably priced at the moment. It's important to remember that the company is a dominant player in the U.S. and the combination of its insurance and services businesses represents a moat or competitive advantage. All of this offers us reason to be confident about this player's long-term story.

Both Burry and Buffett earlier in the year recognized UnitedHealth's potential -- and the good news is that now it's not too late for other investors to follow them into this healthcare stock.

2025-11-05 09:24 4mo ago

2025-11-05 03:56 4mo ago

Invesco International Small-Mid Company Fund Q3 2025 Portfolio Positioning

stocknewsapi

BLHWF DSRLF MTRAF NURAF TCCPY WOLWF WRTBF

SummaryInvesco International Small-Mid Company Fund added six new positions and exited 11 positions during the quarter.We are benchmark independent, bottom-up investors, focusing on company fundamentals rather than using a “top-down” perspective to overweight or underweight any sector or region.We exited AIA Engineering, Belimo, Epiroc, Japan Elevator Service, Kardex, Konami, and Triveni Turbine. We Are/DigitalVision via Getty Images

The following segment was excerpted from Invesco International Small-Mid Company Fund Q3 2025 Commentary.

Portfolio positioning We are benchmark independent, bottom-up investors, focusing on company fundamentals rather than using a “top-down” perspective to overweight or underweight any sector

Recommended For You

2025-11-05 09:24 4mo ago

2025-11-05 03:57 4mo ago

Where Will Chime Financial Stock Be in 5 Years?

stocknewsapi

CHYM

This little fintech has a lot of growth potential.

Chime Financial (CHYM 0.25%) hasn't impressed many investors since its initial public offering (IPO) this June. The provider of mobile banking services went public at $27 a share, but it now trades at around $17.

Chime's business is still growing, but a sequential slowdown in its latest quarter spooked the bulls. Does that pullback represent a good buying opportunity for investors who want to hold its stock for at least five years? Let's review its business model and near-term challenges to decide.

Image source: Getty Images.

How does Chime differ from traditional banks?
Chime provides no-fee checking and savings accounts with overdraft protection, early-pay features (earlier access to direct deposits), and other financial services. It also issues a Visa debit card with no-fee access to over 50,000 ATMs and an entry-level Visa credit card.

The company mainly targets lower-income users who don't have enough cash to open higher-value, no-fee accounts at traditional banks. Its early-pay tools are also useful for people who live paycheck to paycheck, while its credit cards help them gradually build up their credit scores.

Today's Change

(

-0.25

%) $

-0.04

Current Price

$

17.80

But Chime isn't a bank. Its fintech platform streamlines the online banking services from two federally-insured banks: The Bancorp and Stride Bank. These two banks hold and manage all of Chime's accounts.

The company generates most of its revenue by taking a cut of the swipe fees that Visa charges businesses whenever its debit and credit cards are used. A smaller percentage comes from the incentives paid by its banking partners for drawing in more customers.

Did investors overreact to Chime's slowdown?
Chime's growth can be gauged by its number of active members, the purchase volumes on its cards, and its average revenue per active member (ARPAM). Those metrics rose in 2023 and 2024, but its purchase volume and ARPAM dipped sequentially in the second quarter of 2025:

Metric

2023

2024

Q1 2025

Q2 2025

Active members

6.6 million

8 million

8.6 million

8.7 million

Member growth (YOY)

25%

21%

23%

23%

Purchase volume

$92.4 billion

$115.2 billion

$34.5 billion

$32.4 billion

Volume growth (YOY)

29%

25%

18%

18%

ARPAM

$212

$245

$251

$245

ARPAM growth (YOY)

1%

16%

9%

12%

Revenue

$1.28 billion

$1.67 billion

$519 million

$528 million

Revenue growth (YOY)

27%

31%

32%

37%

Data source: Chime Financial. YOY = Year over year.

Management attributed that sequential slowdown to its seasonal headwinds, since tax refunds often drive more spending in the first quarter of each year. That was certainly true last year: In the second quarter of 2024, its total purchase volume and ARPAM declined 3% and 6%, respectively, on a sequential basis. Therefore, that slowdown shouldn't be considered a bright red flag yet.

However, the margin under adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) -- which finally broke even in 2024 and expanded to 5% in the first quarter of 2025 -- still dipped sequentially to 3% in the second quarter as it ramped up its marketing campaigns and expanded its ecosystem with lower-margin features.

That mix of slower growth and higher expenses likely disappointed its growth-focused investors, but the near-term outlook indicates its core business is still firing on all cylinders. For the full year, it expects its revenue to rise from 28% to 29% as its adjusted EBITDA margin expands to 4%.

Where will Chime's stock be in five years?
From 2024 to 2027, analysts expect Chime's revenue to show a compound annual growth rate (CAGR) of 23% to $3.1 billion. They expect its adjusted EBITDA to turn positive in 2025 with a CAGR of 125% to $455 million in 2027. With an enterprise value of $5.4 billion, it still looks undervalued at 2 times next year's sales and 20 times its adjusted EBITDA.

Chime still faces plenty of competition from other fintech apps, like PayPal and Block's Cash App, but there could be plenty of room for these platforms to expand without trampling one another. All of them should continue to pull lower-income customers away from bigger banks, especially if the broader economy weakens.

Assuming Chime matches analysts' estimates through 2027, has a CAGR of 20% through 2031 for revenue, and trades at a more generous 5 times forward sales, its stock could surge nearly sixfold within the next five years and boost its enterprise value to $32.2 billion. So if you believe it can hit those targets as it widens its moat against its competitors, then it's a good idea to accumulate more shares of this fintech as it stagnates below its IPO price.

2025-11-05 09:24 4mo ago

2025-11-05 03:57 4mo ago

Rocket Companies: First End-To-End Mortgage Ecosystem And AI-Driven Efficiency

stocknewsapi

RKT

SummaryRocket Companies is rated a Buy, driven by strong financial momentum, strategic acquisitions, and positive macroeconomic expectations.Recent acquisitions of Redfin and Mr. Cooper create an end-to-end home-buying ecosystem, boosting revenue stability and client recapture.RKT's diversified revenue streams and AI-driven efficiencies position it to benefit from anticipated interest rate cuts and future market recovery.Despite traditional overvaluation metrics, robust growth prospects, and operational leverage, RKT is a compelling long-term investment opportunity. Getty Images

Investment Thesis Rocket Companies, Inc. (RKT) delivered a double beat, reporting EPS of $0.07 and revenue of $1.78 billion. As a result, the company’s stock rose by 5.65% on the day of the earnings release.

My thesis

Analyst’s Disclosure:I/we have a beneficial long position in the shares of RKT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

2025-11-05 09:24 4mo ago

2025-11-05 03:59 4mo ago

Invesco International Small-Mid Company Fund Q3 2025 Top Contributors And Detractors

stocknewsapi

CZMWF ICLR IMCDY LGRDY PNDZF RADLY SSMXY

Comments

SummaryInvesco International Small-Mid Company Fund outperformed most in the real estate and consumer staples sectors due to stock selection.The fund’s underweight in real estate also added to relative return.The fund underperformed most in healthcare, information technology and materials due to stock selection.Invesco is an independent investment management firm dedicated to delivering an investment experience that helps people get more out of life.Be the first to know! Sign up for Invesco US Blog and get expert investment views as they post.Disclosure for all Invesco US articles: Before investing, carefully read the prospectus and/or summary prospectus and carefully consider the investment objectives, risks, charges and expenses. The information provided is for educational purposes only and does not constitute a recommendation of the suitability of any investment strategy for a particular investor. Invesco does not provide tax advice. The tax information contained herein is general and is not exhaustive by nature. Federal and state tax laws are complex and constantly changing. Investors should always consult their own legal or tax professional for information concerning their individual situation. The opinions expressed are those of the authors, are based on current market conditions and are subject to change without notice. These opinions may differ from those of other Invesco investment professionals. NOT FDIC INSURED MAY LOSE VALUE NO BANK GUARANTEE All data provided by Invesco unless otherwise noted. Invesco Distributors, Inc. is the US distributor for Invesco Ltd.’s retail products and collective trust funds. Invesco Advisers, Inc. and other affiliated investment advisers mentioned provide investment advisory services and do not sell securities. Invesco Unit Investment Trusts are distributed by the sponsor, Invesco Capital Markets, Inc., and broker-dealers including Invesco Distributors, Inc. PowerShares® is a registered trademark of Invesco PowerShares Capital Management LLC (Invesco PowerShares). Each entity is an indirect, wholly owned subsidiary of Invesco Ltd. ©2015 Invesco Ltd. All rights reserved.

Recommended For You

2025-11-05 09:24 4mo ago

2025-11-05 04:00 4mo ago

Oculis to Participate in Upcoming November Investor Conferences

stocknewsapi

OCS

November 05, 2025 04:00 ET

| Source:

Oculis Holding AG

ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, announced today that Oculis’ management will participate in upcoming investor conferences in November.

Oculis is pleased to present updates of its innovative, highly differentiated, late-stage portfolio as it enters a pivotal phase in its transformation into a leader in neuro-ophthalmology and ophthalmology. Key highlights include: Privosegtor (PIONEER program) advancement into registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION), following a positive FDA meeting; OCS-01 (DIAMOND registrational trials) topline results for diabetic macular edema expected in Q2 2026; and Licaminlimab (PREDICT-1 registrational trial) in DED anticipated soon, marking the first genotype-based development program to drive precision medicine.

With a strong balance sheet and robust pipeline, Oculis is well-positioned to deliver 6 pivotal readouts with the current funding, to fulfil its mission to save sight and improve eye care with groundbreaking treatments.

Guggenheim Securities 2nd Annual Healthcare Innovation Conference
November 10-12; Boston, U.S.
Fireside chat with Riad Sherif, M.D., Chief Executive Officer, on November 11th at 2:30 pm ET.
Webcast link: Register here.

Stifel Healthcare Conference
November 11-13; New York, U.S.
Fireside chat with Riad Sherif, M.D., Chief Executive Officer, on November 12th at 2:00 pm ET.
Webcast link: Register here.

LifeSci Capital and Sofinnova Partners Growth & Innovation Summit
November 17; London, U.K.
Oculis management will participate in one-to-one meetings.

ICR Healthcare and Sponsors 13th Annual Healthcare Conference
November 17; London, U.K.
Riad Sherif, M.D., Chief Executive Officer, will participate in a panel discussion, entitled ‘Brave New World,’ at 1:50 pm GMT.

The company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

Webcast links, when available, will be posted to the Oculis website on the Events & Presentation page under the Investors & Media section.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing neuro-ophthalmic conditions with significant unmet medical needs. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: Privosegtor, a neuroprotective candidate in the PIONEER program which consists of studies intended to support registration plans for treatment in optic neuropathies like acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases; OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNFα in Phase 2, which is being developed with a genotype-based approach to drive precision medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contact
Ms. Sylvia Cheung, CFO
[email protected]

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
[email protected]

Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
[email protected]

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the development plans for Privosegtor, OCS-01, and Licaminlimab; the initiation, timing, progress and results of clinical trials of Privosegtor, OCS-01, and Licaminlimab; and Oculis’ research and development programs, regulatory and business strategy, future development plans, and management, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (SEC). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

2025-11-05 09:24 4mo ago

2025-11-05 04:00 4mo ago

Nissan and Infobip Achieve 200% Increase in Engagement with AI-Driven WhatsApp Campaign

stocknewsapi

NSANY

VODNJAN, Croatia--(BUSINESS WIRE)--Nissan has redefined customer engagement by partnering with global cloud communications platform Infobip to pioneer a first-of-its-kind Agentic AI campaign. Nissan Kingdom of Saudi Arabia (KSA) leveraged Infobip’s newly launched Conversational AI Gamification, an AI-powered toolset that enables playful, immersive experiences across messaging channels. The marketing campaign utilized Infobip's Vocalize feature, an AI-powered voice game where users competed to win a brand-new Nissan Magnite. Participants used their voices to match an audio waveform to the outline of a car, directly within WhatsApp. This innovative approach transformed lead generation into an engaging competition, driving user participation and brand interaction.

For Nissan KSA, the campaign enhanced brand awareness, increased engagement time, simplified lead acquisition, and stronger brand affinity. The innovative format also provided a cost-effective acquisition channel through chat-based journeys. The campaign achieved remarkable results: a 200% increase in session engagement, a 68% conversion rate from users reaching the competition stage, over 3,400 chatbot sessions, and 1,000 new user profiles created in 5 days.

Ervin Jagatić, AI Business Unit and Product Director at Infobip, said: “Conversational AI Gamification is transforming the way brands can connect with their audiences. By combining AI, voice technology, and gamification, we're enabling global companies like Nissan to create engaging experiences that drive connections, capture valuable user data, and elevate customer experiences."

Karma Al-Ajlani, Deputy General Manager – Customer Experience at Nissan Saudi Arabia, said: “We aimed to boost Magnite awareness and remain top-of-mind. Partnering with Infobip on this pioneering AI-powered WhatsApp voice game has transformed customer engagement; Making it fun, interaction, and rewarding. This demonstrates Nissan Saudi Arabia’s dedication to innovation and superior customer experience.”

Conversational AI Gamification includes two key features. Vocalize, an AI-powered voice game where users match their audio to specific patterns or shapes, and Augmentation, which offers seamless transition from chat to immersive digital environments via smartphone cameras.

The success of the Nissan KSA campaign underscores Infobip's position as a leader in conversational experiences and AI innovation in marketing engagement. By enabling brands to create these unique, interactive campaigns, Infobip is helping its clients lead in digital transformation and customer engagement.

For more information about Infobip: https://www.infobip.com/

2025-11-05 09:24 4mo ago

2025-11-05 04:00 4mo ago

Oculis to Participate in Upcoming November Investor Conferences

stocknewsapi

OCS

ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, announced today that Oculis’ management will participate in upcoming investor conferences in November.

Oculis is pleased to present updates of its innovative, highly differentiated, late-stage portfolio as it enters a pivotal phase in its transformation into a leader in neuro-ophthalmology and ophthalmology. Key highlights include: Privosegtor (PIONEER program) advancement into registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION), following a positive FDA meeting; OCS-01 (DIAMOND registrational trials) topline results for diabetic macular edema expected in Q2 2026; and Licaminlimab (PREDICT-1 registrational trial) in DED anticipated soon, marking the first genotype-based development program to drive precision medicine.

With a strong balance sheet and robust pipeline, Oculis is well-positioned to deliver 6 pivotal readouts with the current funding, to fulfil its mission to save sight and improve eye care with groundbreaking treatments.

Guggenheim Securities 2nd Annual Healthcare Innovation Conference
November 10-12; Boston, U.S.
Fireside chat with Riad Sherif, M.D., Chief Executive Officer, on November 11th at 2:30 pm ET.
Webcast link: Register here.

Stifel Healthcare Conference
November 11-13; New York, U.S.
Fireside chat with Riad Sherif, M.D., Chief Executive Officer, on November 12th at 2:00 pm ET.
Webcast link: Register here.

LifeSci Capital and Sofinnova Partners Growth & Innovation Summit
November 17; London, U.K.
Oculis management will participate in one-to-one meetings.

ICR Healthcare and Sponsors 13th Annual Healthcare Conference
November 17; London, U.K.
Riad Sherif, M.D., Chief Executive Officer, will participate in a panel discussion, entitled ‘Brave New World,’ at 1:50 pm GMT.

The company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

Webcast links, when available, will be posted to the Oculis website on the Events & Presentation page under the Investors & Media section.

-END-

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing neuro-ophthalmic conditions with significant unmet medical needs. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: Privosegtor, a neuroprotective candidate in the PIONEER program which consists of studies intended to support registration plans for treatment in optic neuropathies like acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases; OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNFα in Phase 2, which is being developed with a genotype-based approach to drive precision medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contact
Ms. Sylvia Cheung, CFO
[email protected]

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
[email protected]

Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
[email protected]

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the development plans for Privosegtor, OCS-01, and Licaminlimab; the initiation, timing, progress and results of clinical trials of Privosegtor, OCS-01, and Licaminlimab; and Oculis’ research and development programs, regulatory and business strategy, future development plans, and management, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (SEC). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

2025-11-05 09:24 4mo ago

2025-11-05 04:00 4mo ago

Sunlands Technology Group to Report Third Quarter 2025 Financial Results on Thursday, November 20, 2025

stocknewsapi

STG

BEIJING, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sunlands Technology Group (NYSE: STG) ("Sunlands" or the "Company"), a leader in China's adult online education market and China's adult personal interest learning market, today announced that it will report its third quarter 2025 unaudited financial results on Thursday, November 20, 2025, before the open of U.S. markets.

Sunlands' management team will host a conference call at 7:00 a.m. U.S. Eastern Time, (8:00 p.m. Beijing/Hong Kong time) on November 20, 2025, following the quarterly results announcement.

For participants who wish to join the call, please access the link provided below to complete online registration 30 minutes prior to the scheduled call start time. Upon registration, participants will receive details for the conference call, including dial-in numbers, a personal PIN and an e-mail with detailed instructions to join the conference call.

Registration Link:

https://register-conf.media-server.com/register/BI8300e40c73ed4950972d9e8dd3b708b8

Additionally, a live webcast and archive of the conference call will be available on the Investor Relations section of Sunlands' website at https://ir.sunlands.com/.

About Sunlands

Sunlands Technology Group (NYSE: STG) ("Sunlands" or the "Company"), formerly known as Sunlands Online Education Group, is a leader in China's adult online education market and China's adult personal interest learning market. With a one to many, live streaming platform, Sunlands offers online professional courses and educational content, including various interest courses, aimed at preparing students for professional certification exams, enhancing their professional skills, and catering to their personal interests, as well as various degree- or diploma-oriented post-secondary courses. Students can access its services either through PC or mobile applications. The Company's online platform cultivates a personalized, interactive learning environment by featuring a virtual learning community and a vast library of educational content offerings that adapt to the learning habits of its students. Sunlands offers a unique approach to education research and development that organizes subject content into Learning Outcome Trees, the Company's proprietary knowledge management system. Sunlands has a deep understanding of the educational needs of its prospective students and offers solutions that help them achieve their goals.

For investor and media inquiries, please contact:

Sunlands Technology Group
Investor Relations
Email: [email protected]

SOURCE: Sunlands Technology Group

2025-11-05 09:24 4mo ago

2025-11-05 04:04 4mo ago

XPeng Gears Up to Launch Robotaxis Next Year

stocknewsapi

XPEV

The Nasdaq-listed company is set to become the first Chinese carmaker to launch a self-developed robotaxi.

2025-11-05 09:24 4mo ago

2025-11-05 04:05 4mo ago

Orsted swings to quarterly net loss as Trump's offshore wind battle takes its toll

stocknewsapi

DNNGY DOGEF

Danish renewables giant Orsted on Wednesday reported a quarterly net loss as the beleaguered company continues to battle U.S. President Donald Trump's anti-wind policies.

The world's biggest offshore wind farm group posted a net loss of 1.7 billion Danish kroner ($261.8 million) for the July-September period. The result, which was slightly better than analysts feared, was significantly down from profit of 5.17 billion Danish kroner in the same period last year.

Orsted flagged third-quarter impairment costs of nearly 1.8 billion Danish kroner.

The company, however, reiterated its full-year earnings before interest, taxes, depreciation, and amortization (EBITDA) guidance of 24-27 billion Danish kroner, excluding earnings from new partnerships and cancellation fees.

It comes shortly after the company announced it had reached a deal to sell a 50% stake in its Hornsea 3 offshore wind farm in the U.K. to Apollo Global Management in a deal worth $6 billion.

"I'm satisfied with the good progress across our entire construction portfolio and our solid operational performance," Orsted CEO Rasmus Errboe said in a statement.

"Our key focus is to continue delivering on our business plan, which will enable Ørsted to remain a global leader of offshore wind with a strong foothold in Europe," he added.

Shares of Orsted were 1.2% higher on Wednesday morning. The stock price has fallen sharply this year amid concerted efforts from the White House to halt several ongoing developments and suspend new licensing.

2025-11-05 09:24 4mo ago

2025-11-05 04:05 4mo ago

Xenia Hotels Bets On Buybacks Amid Sluggish Recovery

stocknewsapi

XHR

2025-11-05 09:24 4mo ago

2025-11-05 04:06 4mo ago

Petro Matad falls 11% despite new production from Gazelle well

stocknewsapi

PRTDF

Shares in Petro Matad Limited (AIM:MATD, OTC:PRTDF) slipped 11% to 1.4p after the Mongolia-focused oil producer reported mixed operational news, with a new well starting production but continued challenges at another site.

The AIM-quoted explorer said its Gazelle-1 well, tested in October, has been brought online at an initial rate of around 200 barrels of oil per day.

Early shipments have been delivered to PetroChina under an existing sales agreement, and the company is monitoring performance to see if output can be increased.

However, progress at the Heron-2 well has been slower than hoped. After early signs of oil recovery, flow rates dropped due to a possible downhole issue or perforation blockage.

Pumping operations have resumed, but if output does not improve, the well will be shut in for the winter.

Heron-1, which has now been producing for a year, continues to perform steadily with total output close to 60,000 barrels and a low water cut of about 3%.

Petro Matad is also renegotiating payment terms with PetroChina to ensure full and timely settlement for exported crude.

Chief executive Mike Buck said production growth and cash generation remain the focus as the company works through operational and contractual hurdles.

2025-11-05 09:24 4mo ago

2025-11-05 04:14 4mo ago

Scorpio Tankers: Entering A Mature Phase With Stable Dividends Ahead

stocknewsapi

STNG

SummaryScorpio Tankers reported Q3 2025 results showing lower profits but a significantly stronger balance sheet and increased dividend to $0.42 per share.STNG continues aggressive debt reduction, maintains minimal CAPEX, and prioritizes financial stability with cash reserves of $626.7 million and net debt down to $255 million.Despite normalized TCE rates post-2024, the company remains flexible, effective, and undervalued relative to peers, with strong fundamentals and a modern fleet.I rate STNG as a buy, viewing it as a mature, low-leverage dividend stock with upside potential and robust shareholder value support.Dikuch/iStock via Getty Images

Scorpio Tankers (STNG) Q3 2025 results gave me some mixed feelings. profitability went down, but the balance became stronger than ever. The company is continuing aggressive debt reduction, accumulates cash and increases its liquidity. CAPEX seems to be moderate

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

2025-11-05 09:24 4mo ago

2025-11-05 04:15 4mo ago

Nordea targets return on equity of above 15% in 2026-2030

stocknewsapi

NRBAY

A view of a Nordea logo above one of its branches in Lund, Sweden, October 16, 2023. REUTERS/ Tom Little/File Photo Purchase Licensing Rights, opens new tab

CompaniesNov 5 (Reuters) - Nordea

(NDAFI.HE), opens new tab, the Nordic region's biggest bank, is targeting a return on equity of above 15% between 2026 and 2030, and significantly above that in 2030, it said in a statement ahead of its investor day on Wednesday.

Nordea will target profitable growth in each of its businesses, the bank said, with a special focus in Norway and Sweden, its biggest market.

Sign up here.

The bank also said it expects a cost-to-income ratio of 40–42% in 2030, excluding regulatory fees.

It said the new targets would be supported by a 60–70% annual dividend payout ratio, and semi-annual dividend distributions, and more than 20 billion euros ($23 billion) in total shareholder distributions during 2026-30.

The bank's interim dividend will be based upon 50% of its first-half profit for the financial year, it said.

Nordea's shares fell around 3% in early trade in Helsinki, the worst performer on the Helsinki blue-chip index

(.OMXH25), opens new tab.

The bank said that it expects its core tier 1 ratio, a key measure of its financial strength, to about 15.5% throughout the five-year period.

($1 = 0.8575 euros)

Reporting by Elviira Luoma in Gdansk, editing by Matt Scuffham

Our Standards: The Thomson Reuters Trust Principles., opens new tab

2025-11-05 09:24 4mo ago

2025-11-05 04:17 4mo ago

Nu Holdings Q3 Preview: Margin Expansion Could Drive The Next Re-Rating

stocknewsapi

Analyst’s Disclosure:I/we have a beneficial long position in the shares of NU, ITUB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

2025-11-05 09:24 4mo ago

2025-11-05 04:20 4mo ago

Revolve Group, Inc. (RVLV) Q3 2025 Earnings Call Transcript

stocknewsapi

RVLV

Q3: 2025-11-04 Earnings SummaryEPS of $0.30 beats by $0.17

|

Revenue of

$295.63M

(4.41% Y/Y)

misses by $2.10M

Revolve Group, Inc. (RVLV) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST

Company Participants

Erik Randerson - Vice President of Investor Relations
Michael Mente - Co-Founder, Co-CEO & Director
Michael Karanikolas - Co-Founder, Co-CEO & Chairman of the Board
Jesse Timmermans - Chief Financial Officer

Conference Call Participants

Rakesh Patel - Raymond James & Associates, Inc., Research Division
Oliver Chen - TD Cowen, Research Division
Matt Koranda - ROTH Capital Partners, LLC, Research Division
Michael Binetti - Evercore Inc.
Janine Hoffman Stichter - BTIG, LLC, Research Division
Anna Andreeva - Piper Sandler & Co., Research Division
Kavya Narayanan - Morgan Stanley, Research Division
Jay Sole - UBS Investment Bank, Research Division
Peter McGoldrick - Stifel, Nicolaus & Company, Incorporated, Research Division
Mary Sport - BofA Securities, Research Division

Presentation

Operator

Ladies and gentlemen, thank you for standing by. My name is Abby, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Revolve Group Third Quarter 2025 Earnings Call. [Operator Instructions]

I would now like to turn the conference over to Erik Randerson, Senior Vice President of Investor Relations. You may begin.

Erik Randerson
Vice President of Investor Relations

Good afternoon, everyone, and thanks for joining us to discuss Revolve's third quarter 2025 results. Before we begin, I'd like to mention that we have posted a presentation containing Q3 2025 financial highlights to our Investor Relations website located at investors.revolve.com.

I'd also like to remind you that this conference call will include forward-looking statements, including statements related to our future growth, our inventory balance, our key priorities and business initiatives, industry trends, the impact of tariffs and our mitigation efforts, our marketing events and their expected impact, our physical retail stores and our outlook for net sales, gross margin, operating expenses and effective tax rate.

These statements are subject to

Recommended For You

2025-11-05 09:24 4mo ago

2025-11-05 04:20 4mo ago

PTC Therapeutics, Inc. (PTCT) Q3 2025 Earnings Call Transcript

stocknewsapi

PTCT

Q3: 2025-11-04 Earnings SummaryEPS of $0.19 beats by $1.30

|

Revenue of

$211.01M

(7.23% Y/Y)

beats by $35.49M

PTC Therapeutics, Inc. (PTCT) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST

Company Participants

Ellen Cavaleri
Matthew Klein - CEO & Director
Eric Pauwels - Chief Business Officer
Pierre Gravier - Chief Financial Officer

Conference Call Participants

Kristen Kluska - Cantor Fitzgerald & Co., Research Division
Tazeen Ahmad - BofA Securities, Research Division
Brian Abrahams - RBC Capital Markets, Research Division
Lut Ming Cheng - JPMorgan Chase & Co, Research Division
Judah Frommer - Morgan Stanley, Research Division
Yuxi Dong - Jefferies LLC, Research Division
Kyuwon Choi - Goldman Sachs Group, Inc., Research Division
Joon Lee - Truist Securities, Inc., Research Division
Huidong Wang - Barclays Bank PLC, Research Division
Samantha Corwin - William Blair & Company L.L.C., Research Division
Joseph Schwartz - Leerink Partners LLC, Research Division
John Peyton Bohnsack - TD Cowen, Research Division
Luke Herrmann - Robert W. Baird & Co. Incorporated, Research Division

Presentation

Operator

Ladies and gentlemen, thank you for standing by. Welcome to PTC Therapeutics Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Today's call is being recorded.

I would now like to turn the call over to Ellen Cavaleri, Head of Investor Relations. Please go ahead.

Ellen Cavaleri

Good afternoon, and thank you for joining us to discuss PTC Therapeutics' Third Quarter 2025 Corporate Update and Financial Results. I'm joined today by our Chief Executive Officer, Dr. Matthew Klein; our Chief Business Officer, Eric Pauwels; and our Chief Financial Officer, Pierre Gravier.

Today's call will include forward-looking statements based on our current expectations. These statements are subject to certain risks and uncertainties, and actual results may differ materially.

Please review the slide posted on our Investor Relations website in conjunction with the call, which contains information about our forward-looking statements, our most recent quarterly report on Form 10-Q and annual report on Form 10-K filed with the SEC as well as our other SEC filings

Recommended For You

2025-11-05 09:24 4mo ago

2025-11-05 04:21 4mo ago

Laureate Education: Unlocking Value Through Campus Expansion And Buybacks

stocknewsapi

LAUR

SummaryLaureate Education (LAUR) achieved 8.5% YoY revenue growth in Q3, driven by strong enrollment increases in Mexico and Peru.
Enrollment surged 7% YoY, with total YTD enrollments reaching 511,000, supporting a positive outlook for LAUR.
Adjusted net income rose 11% YoY, reflecting cost discipline despite margin pressure and the absence of prior-year one-time tax benefits.
Share repurchase program expanded by $150MM; $177MM remaining capacity signals undervaluation.
Strong Buy maintained on enrollment momentum, expansion pipeline, and undervalued growth outlook.
Pgiam/iStock Unreleased via Getty Images

I initiated my coverage for Laureate Education Inc. (NASDAQ:LAUR) on August 9. I issued a Strong Buy rating, which turned out to be successful as the stock provided 17.8% return compared to S&P 7.3%. I previously

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

2025-11-05 08:24 4mo ago

2025-11-05 02:39 4mo ago

Sinopec Signs Deals Worth US$40.9 Billion at CIIE 2025

stocknewsapi

SNPMF

, /PRNewswire/ -- China Petroleum & Chemical Corporation (HKG: 0386, "Sinopec") hosted a themed forum and a signing ceremony on November 4 at the 8th China International Import Expo (CIIE 2025). The Company signed purchasing contracts with 34 partners from 17 countries and regions, which totaled US$40.9 billion, including 24 products from 10 major categories, including crude oil, chemicals, equipment, materials, consumer goods and more. Since the first CIIE in 2018, Sinopec has signed orders exceeding a total of US$325 billion in eight sessions.

Sinopec Signs Deals Worth US$40.9 Billion at CIIE 2025.

Centered on the theme Technology Driven, AI Empowered: The Future of Energy, the forum focused on digital intelligence, technological innovation, new materials R&D, supply chain resilience enhancement, and exploring deeper international energy cooperation.

Zhao Dong, vice chairman and president of Sinopec, delivered a speech at the forum, which was moderated by Li Yonglin, director and senior vice president of Sinopec. Niu Shuanwen, director and senior vice president of Sinopec, attended the event and signed agreements with international partners.

"Sinopec is firmly committed to its primary mission of promoting high‑quality development. While continuing to consolidate the industrial foundation leveraging technological strength, the group also adheres to the principle of 'digital intelligence empowerment' to activate new engines of value creation, striving to advance the energy and chemical industry toward greater sophistication, intelligence, and sustainability," remarked Zhao Dong.

He emphasized that Sinopec's development is inseparable from the long‑term trust and strong support of global partners. Looking ahead to China's 15th Five‑Year Plan period, Zhao Dong outlined Sinopec's goal to work with all parties to strengthen scientific and technological innovation, break developmental bottlenecks, and build new industry advantages.

Zhao Dong also called for joint efforts to accelerate the pace of digital intelligence empowerment, promote deep integration of next‑generation information technology with the energy and chemical industry, and stimulate new drivers for industrial upgrading. Zhao Dong said Sinopec will expand green and low‑carbon cooperation, advancing clean and efficient use of traditional energy in parallel with the large‑scale development of new energy, thereby creating a sustainable development blueprint and a bright future for the energy and chemical industry.

Senior executives from leading firms—Datuk Sazali Hamzah (EVP & CEO Downstream, Petronas Chemicals Group), Axel Lorenz (CEO, Process Automation, Siemens), Aravind Yarlagadda (SVP, Industrial Solutions, Baker Hughes), and Audun M. Martinsen (Partner and Head of Energy Service Research, Rystad Energy)—delivered keynote speeches.

SOURCE SINOPEC

2025-11-05 08:24 4mo ago

2025-11-05 02:39 4mo ago

Alamos Gold: Top-Quality Gold Miner Trading Below Fair Value With Strong Organic Growth

stocknewsapi

AGI

SummaryAlamos Gold remains a Buy, trading below fair value despite a recent production cut and strong gold price gains.AGI boasts a robust financial position, low-cost operations, and a promising organic growth pipeline, targeting ~700,000 ounces by 2027.Temporary setbacks such as the downtime at Magino and Island Gold are not fundamental issues and do not alter the company's long-term potential, but they came at a terrible time.Even if gold prices decline, AGI's organic growth should offset it, while potential for higher gold prices could unlock significant upside for the stock.Analyst’s Disclosure:I/we have a beneficial long position in the shares of AGI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

2025-11-05 08:24 4mo ago

2025-11-05 02:41 4mo ago

Orsted Swings to Loss Following U.S. Stop-Work Order, But Stays Upbeat for Full Year

stocknewsapi

DNNGY DOGEF

The renewable-energy company said it remained confident of reaching its full-year targets.

2025-11-05 08:24 4mo ago

2025-11-05 02:41 4mo ago

French satellite operator Eutelsat taps Imerys exec as next finance chief

stocknewsapi

ETCMY EUTLF IMYSF

Eutelsat has appointed Sébastien Rouge as its new Chief Financial Officer, the French satellite operator said on Wednesday.

2025-11-05 08:24 4mo ago

2025-11-05 02:42 4mo ago

Nvidia deepens India focus with $2 billion Deep Tech Alliance partnership

stocknewsapi

NVDA

Nvidia is expanding its footprint in India by joining a $2 billion investment alliance focused on deep technology, according to CNBC. As a founding member of the India Deep Tech Alliance (IDTA), the US chipmaker aims to mentor startups building solutions in semiconductors, artificial intelligence, biotechnology, space, robotics, and energy.

2025-11-05 08:24 4mo ago

2025-11-05 02:44 4mo ago

Johnson Controls Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

stocknewsapi

JCI

Johnson Controls International plc (NYSE:JCI) will release earnings results for the fourth quarter before the opening bell on Wednesday, Nov. 5.

Analysts expect the Cork, Ireland-based company to report quarterly earnings at $1.20 per share, down from $1.28 per share in the year-ago period. The consensus estimate for Johnson Controls' quarterly revenue is $6.33 billion, compared to $7.39 billion a year earlier, according to Benzinga Pro.

On Sept. 24, Johnson Controls announced the appointment of Todd Grabowski as vice president and president, Americas.

Shares of Johnson Controls fell 1.9% to close at $111.04 on Tuesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

JP Morgan analyst Stephen Tusa maintained an Overweight rating and raised the price target from $105 to $125 on Oct. 15, 2025. This analyst has an accuracy rate of 69%.
Citigroup analyst Andrew Kaplowitz maintained a Neutral rating and increased the price target from $112 to $119 on Oct. 9, 2025. This analyst has an accuracy rate of 84%.
Morgan Stanley analyst Chris Snyder maintained an Overweight rating and increased the price target from $115 to $125 on Aug. 21, 2025. This analyst has an accuracy rate of 77%.
RBC Capital analyst Deane Dray maintained a Sector Perform rating and increased the price target from $112 to $114 on July 30, 2025. This analyst has an accuracy rate of 69%.
Barclays analyst Julian Mitchell maintained an Equal-Weight rating and raised the price target from $100 to $101 on July 30, 2025. This analyst has an accuracy rate of 73%
Considering buying JCI stock? Here’s what analysts think:

Read This Next:

Top 2 Industrials Stocks You May Want To Dump This Quarter
Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

2025-11-05 08:24 4mo ago

2025-11-05 02:46 4mo ago

Challenger Limited (CFIGY) Shareholder/Analyst Call Transcript

stocknewsapi

CFIGF

Challenger Limited (OTCPK:CFIGY) Shareholder/Analyst Call November 4, 2025 5:30 PM EST

Company Participants

Mark Chen - General Manager of Investor Relations
Nick Hamilton - MD, CEO & Director
Alexandra Bell - Chief Financial Officer
Anton Kapel - Chief Executive of Insurance

Conference Call Participants

Freya Kong - BofA Securities, Research Division
Kieren Chidgey - UBS Investment Bank, Research Division
Siddharth Parameswaran - JPMorgan Chase & Co, Research Division
Julian Braganza - Goldman Sachs Group, Inc., Research Division
Lafitani Sotiriou - MST Financial Services Pty Limited, Research Division
Simon Fitzgerald - Jefferies LLC, Research Division
Andrei Stadnik - Morgan Stanley, Research Division
Marcus Barnard - Bell Potter Securities Limited, Research Division

Presentation

Mark Chen
General Manager of Investor Relations

Good morning, everyone, and welcome to those joining online to Challenger's market briefing on APRA's proposed capital standards for longevity Products. I'm Mark Chen, Challenger's General Manager of Investor Relations. We're coming to you today from our Martin Place head office in Sydney.

Before we begin, I would like to acknowledge the Gadigal people of the Eora Nation, the traditional custodians of the land on which we are hosting this event today and pay my respects to both elders, past and present.

Today's briefing will be followed by a Q&A session that will only be open to analysts and investors. To ask a question you'll need to have joined via the telephone. As a reminder, today's briefing is based on APRA's proposed capital standards issued last week. We are currently in consultation with APRA with written submissions on these proposed reforms due by 17th of December. As such, there are certain subjects we will be unable to provide responses to, which the teams are working on or that require Challenger Board or APRA approval. These are areas such as target ranges, risk appetite, asset allocation, capital allocation. We will use the session to provide points of clarification of guidance, including the use of illustrative

Recommended For You

2025-11-05 08:24 4mo ago

2025-11-05 02:49 4mo ago

Veris Residential: Shares Have Potential, But Are Fully Priced

stocknewsapi

VRE

2025-11-05 08:24 4mo ago

2025-11-05 02:52 4mo ago

M&S reveals cost of cyber attack as profit almost wiped out

stocknewsapi

MAKSY

The cyber attack on high street department store Marks and Spencer is expected to directly cost roughly £136m.

The figure is only the cost of immediate incident systems response and recovery, as well as specialist legal
and professional services support.

Combined with a loss in sales, as the retailer's online systems were out of action from Easter into the summer, statutory profit before tax at the business has been nearly wiped out for the first half of the year.

This profit measure dropped from £391.9m last year to £3.4m this year.

About £100m is being claimed back in insurance for the cyberattack, M&S said in its market update.

This breaking news story is being updated and more details will be published shortly.

Please refresh the page for the latest version.

You can receive breaking news alerts on a smartphone or tablet via the Sky News app. You can also follow us on WhatsApp and subscribe to our YouTube channel to keep up with the latest news.

2025-11-05 08:24 4mo ago

2025-11-05 02:55 4mo ago

Kingman Minerals Prepares for Drilling at High-Grade Mohave Project amid Record Gold Prices

stocknewsapi

KGSSF

November 05, 2025 2:55 AM EST | Source: Kingman Minerals Ltd.
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2025) - Kingman Minerals Ltd. (TSXV: KGS) (OTCQB: KGSSF) (FSE: 47A) ("Kingman" or the "Company") is pleased to update shareholders on the significant progress to date at its flagship Mohave Project in Mohave County, Arizona, which includes the historic Rosebud Mine. Given the current strength in the gold market, Kingman believes the Mohave Project is exceptionally well-positioned for near-term value creation.

Historic High-Grade District with Substantial Upside

The Mohave Project comprises 72 lode claims (1467 acres or 594 hectares), inclusive of the historic Rosebud Mine. The underground workings include over 2,300 feet of drifts, raises, and crosscuts. Historical (non-NI 43-101) data suggest a potential for up to 664,000 ounces of gold and 2.6 million ounces of silver across multiple parallel vein structures.1

Kingman's focus is to continue to replicate and validate these historic values, then expand and upgrade them according to modern exploration standards.

Modern Work Programs & High-Grade Sampling Results

Kingman has executed multiple phases of work to date, including two underground reconnaissance programs and two drilling phases, both confirming high-grade gold and silver intercepts at depth. Underground sampling from mineralized veins returned exceptional results, including 688 g/t Au and 468 g/t Ag over 0.18 m, and 252 g/t Au and 341 g/t Ag over 0.46 m.

Phase 1 Underground Reconnaissance & Sampling
Confirmed access to historic workings and collected high-grade channel and chip samples. A standout result was **252 g/t Au + 341 g/t Ag over 0.46 m** on the 100 ft level of the Rosebud Mine.2Phase 2 Underground Reconnaissance & Sampling
Expanded sampling efforts on the 100 ft and 200 ft levels, clearing debris to access lower levels, and sending assays to ALS Laboratories (method ME-GRA21).3Key highlights include:

SampleLevelWidth (m)Au (g/t) Ag (g/t) RB200-11100 ft, N Stope0.18 m **688 g/t****468 g/t**RB200-10100 ft, N Stope0.15 m 109 g/t 164 g/t RB200-13100 ft, N Stope0.28 m 70.5 g/t 93 g/t RB200-4 100 ft 0.25 m 2.88 g/t 133 g/t These values confirm the presence of bonanza-grade veins, supporting the historic high grades and underscoring the vertical and lateral continuity potential.3

This combination of strong assay results across multiple locations lays the foundation to validate, expand, and define the resource.

With gold prices at or near record levels and many analysts' forecasting further upside, projects with proven high-grade potential in stable jurisdictions are attracting increased investor attention. The Mohave Project's location in Arizona—with good infrastructure and a favorable mining climate—further strengthens its development profile.

By converting historic grades into NI 43-101-compliant resources in the near term, Kingman will proceed with extensive exploration work. The high grades seen in both Phase 1 and Phase 2, combined with the modelled continuity from 3D surveys, provide multiple pathways for upside—whether by expanding the known veins, identifying parallel structures, or exploring extensions downward.

"We are excited to advance work at Mohave and bring clarity to a district with truly exceptional grade potential," said Simon Studer, Interim CEO of Kingman Minerals Ltd. "Our underground sampling already underscores bonanza-grade zones in multiple places, and the updated mapping and digital modelling give us confidence in targeting these veins for drilling. With gold markets in a strong uptrend, we anticipate drilling to convert this potential into value for our shareholders."

TECHNICAL INFORMATION

The technical information in this website has been prepared in accordance with the Canadian regulatory requirements set out in National Instrument 43-101 and reviewed on behalf of the company by, Qualified Person: Bradley C. Peek, MSc. CPG Qualified Person for Kingman Minerals Ltd.

ABOUT

Kingman Minerals Ltd. (TSXV: KGS) is a publicly traded exploration and development company focused on precious metals in North America. The company's flagship project is the fully owned historic Rosebud Mine, located in the Music Mountains, Mohave County, Arizona. High-grade gold and silver veins were discovered in the area in the 1880's and were mined mainly in the late 20's and 30's. Underground development on the Rosebud property included a 400-foot shaft and approximately 2,500 feet of drifts, raises, and crosscuts. The company believes that to explore the full potential of the area, drilling and sampling along strike and depth extensions of existing and additional vein structures is essential.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking information which is not comprised of historical facts. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release includes statements regarding, among other things, the completion transactions completed in the Agreement.Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, regulatory approval processes. Although Kingman believes that the assumptions used in preparing the forward-looking information in this news release are reasonable, including that all necessary regulatory approvals will be obtained in a timely manner, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Kingman disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by applicable securities laws.

1: https://kingmanminerals.com/projects/mohave-project/?utm_source=chatgpt.com "Mohave Project"
2: https://finance.yahoo.com/news/2nd-sampling-program-results-mohave-065500480.html?utm_source=chatgpt.com "2nd Sampling Program Results Mohave Project Mine Shaft ..."
3: https://kingmanminerals.com/projects/mohave-project/2nd-phase-underground-reconnaissance-sampling-program/?utm_source=chatgpt.com "2nd Phase Underground Reconnaissance & Sampling"

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273234

2025-11-05 08:24 4mo ago

2025-11-05 02:56 4mo ago

The Baldwin Insurance Group, Inc. (BWIN) Q3 2025 Earnings Call Transcript

stocknewsapi

BWIN

Q3: 2025-11-04 Earnings SummaryEPS of $0.31 misses by $0.00

|

Revenue of

$365.39M

(7.80% Y/Y)

beats by $1.69M

The Baldwin Insurance Group, Inc. (BWIN) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST

Company Participants

Bonnie Bishop - Executive Director of Investor Relations
Trevor Baldwin - CEO & Non-Independent Director
Bradford Hale - Chief Financial Officer

Conference Call Participants

Charles Peters - Raymond James & Associates, Inc., Research Division
Charles Lederer - BMO Capital Markets Equity Research
Elyse Greenspan - Wells Fargo Securities, LLC, Research Division
Pablo Singzon - JPMorgan Chase & Co, Research Division
Andrew Andersen - Jefferies LLC, Research Division
Brian Meredith - UBS Investment Bank, Research Division
Thomas Mcjoynt-Griffith - Keefe, Bruyette, & Woods, Inc., Research Division

Presentation

Operator

Ladies and gentlemen, greetings, and welcome to the Baldwin Group Third Quarter 2025 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Bonnie Bishop, Executive Director, Investor Relations. Please go ahead.

Bonnie Bishop
Executive Director of Investor Relations

Thank you. Welcome to the Baldwin Group's Third Quarter 2025 Earnings Call. Today's call is being recorded.

Third quarter financial results, supplemental information and Form 10-Q were issued earlier this afternoon and are available on the company's website at ir.baldwin.com. Please note that remarks made today may include forward-looking statements subject to various assumptions, risks and uncertainties, including, for example, our strategy with respect to our capital allocation in the future. The company's actual results may differ materially from those contemplated by such statements. For a more detailed discussion, please refer to the note regarding forward-looking statements in the company's earnings release and our most recent Form 10-Q, both of which are available on the Baldwin website.

During the call today, the company may also discuss certain non-GAAP financial measures. For a more detailed discussion of these non-GAAP financial measures and historical reconciliation to the most closely comparable GAAP measures, please refer to the

Recommended For You

2025-11-05 08:24 4mo ago

2025-11-05 02:58 4mo ago

Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential

stocknewsapi

MBGPF

, /PRNewswire/ -- Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of MOB-015 (Terclara®) in Europe. The agreement comprises 19 European markets, enabling a coordinated launch across all key EU markets under the leading global antifungal brand Lamisil®.

The agreement covers 19 European markets, representing a total population of approximately 500 million people including all major EU countries and the United Kingdom ("Big 5") as well as the eleven countries where Terclara® is already approved but not yet launched. This provides Moberg Pharma the opportunity for a coordinated launch in all key European markets. Karo Healthcare will be responsible for marketing, distribution and sales throughout Europe. Financial terms are not disclosed, but the agreement includes royalties and compensation for delivered products.

"We are very pleased to enter this partnership with Karo Healthcare, which has a strong commercial presence across Europe. Launching MOB-015/Terclara® under the well-known Lamisil® brand gives us an exceptional opportunity to establish the product as the market leader also beyond Sweden and Norway," says Anna Ljung, CEO of Moberg Pharma.

"Moberg Pharma has developed a unique and clinically well-documented product. Being able to launch MOB-015/Terclara® under the Lamisil® brand is a perfect combination of scientific innovation and commercial strength that gives us a unique position in the market," says Christoffer Lorenzen, CEO of Karo.

The Lamisil® brand
Terbinafine, originally developed and launched by Novartis under the Lamisil® brand, has long been considered the gold standard treatment for skin and foot fungal infections such as athlete's foot and nail fungus. Lamisil® is present in more than 60 markets worldwide and has become synonymous with its active ingredient, terbinafine, while consistently standing at the forefront of antifungal research and innovation.

MOB-015/Terclara®, developed by Moberg Pharma, represents the next generation of terbinafine therapy – a new topical formulation. Oral treatment of nail fungus is associated with risks such as interactions with other medications and liver damage, which are avoided with topical treatment. Previous attempts at topical treatment with terbinafine have failed due to the difficulty of delivering a sufficient amount of the active substance through the nail. MOB-015 is the first topical treatment that has achieved mycological cure on par with oral treatment, with 76% of patients achieving mycological cure in the registration studies. It is therefore particularly satisfying to launch the product under the strong and fitting Lamisil® brand.

Launch and regulatory steps
Launching MOB-015/Terclara® under the Lamisil® brand, wherever possible, optimizes the product's chances to take a leading position in major European markets. However, the use of the Lamisil® brand for this pharmaceutical product requires approval by the respective national health authorities, which affects the timing of the launch. Both companies intend to initiate launch as soon as possible.

The companies will also collaborate to expand current marketing authorizations to additional countries as soon as feasible. For regulatory reasons, markets that are already approved have priority, since new countries cannot be added while a name change or other changes are being implemented.

Although the product will be launched under the Lamisil® brand, the connection to Moberg Pharma will be made clear through the marketing concept 'Powered by Terclara®'.

A partnership with strong European reach
Karo Healthcare is a leading European consumer healthcare company, backed by KKR, a leading global investment firm, and with ambitious growth plans across Europe. With established distribution in all major European pharmacy chains, Karo has the capacity to manage both prescription and over-the-counter products, including prescription-to-nonprescription (Rx-to-OTC) switches.

Through this partnership with Karo Healthcare, the product gains broad market coverage and effective distribution right from the outset, which would take Moberg Pharma time to build up on its own. While Moberg Pharma will not launch Terclara® on its own in Europe as part of this collaboration, the company still plans to play an active commercial role in other territories, particularly in the U.S., as part of its long-term strategy.

The agreement marks an important milestone in Moberg Pharma's commercial expansion and lays the foundation to establish MOB-015/Terclara® as the new market leader in the treatment of nail fungus across Europe.

About this information
Moberg Pharma is releasing this information in accordance with the EU's Market Abuse Regulation (MAR). The information was released for public distribution through the contact named below at 8.30 a.m. CET on November 5th, 2025.

For additional information, please contact:
Anna Ljung, CEO, Phone: +46 8 522 307 01, E-mail: [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/moberg-pharma/r/moberg-pharma-and-karo-healthcare-enter-exclusive-license-agreement-for-mob-015-terclara-in-europe--,c4261942

The following files are available for download:

SOURCE Moberg Pharma

2025-11-05 08:24 4mo ago

2025-11-05 02:58 4mo ago

Marks & Spencer hikes dividend as cyber attack recovery almost complete

stocknewsapi

MAKSY

Marks and Spencer Group PLC (LSE:MKS) reported stronger first-half profits than expected, after the retailer quickly settled its insurance claim at £100 million for the cyber attack that laid it low in the spring.

The FTSE 100-listed group generated an adjusted pre-tax profit of £184.1 million in the 26 weeks to 27 September, down from £413.1 million last year as the cyber incident led to some empty shelves as systems were taken offline to thwart attackers.

Despite the attack, group sales jumped 22% to £7.97 billion.

Food sales, which increased 7.8% and generated an adjusted operating profit of £89.1 million as margins declined to 2.0% from 5.1%. In current trading, margins were said to now be almost back to normal.

Fashion, Home & Beauty sales declined 16.4%, but still made a profit from that division at £46.1 million despite margins falling to 2.7% from 12%. The recovery in this arm has been slower, the M&S said, "as systems complexity means it has taken time to smooth the flow of stock".

International sales also fell, down 11.6% with profit at £13.3 million, while Ocado Retail posted a £3.1 million operating loss before adjustments.

The cyber incident led to £101.6 million in related costs.

Reflecting the recovery, the board increased the interim dividend 20% to 1.2p.

“The first half of this year was an extraordinary moment in time for M&S,” said chief executive Stuart Machin. “In the second half, we expect profit to be at least in line with last year.”

In the fact of the disruption, he hailed further progress on the “Reshape for Growth” strategy, including a £340 million investment in its food supply chain and opening six new stores in the first half. A further 12 are planned before the end of the financial year.

Machin added: “Our plan to reshape M&S for long-term sustainable growth is unchanged, our ambitions are undimmed, and our determination to knuckle down and deliver is stronger than ever.”

2025-11-05 08:24 4mo ago

2025-11-05 02:59 4mo ago

Top Wall Street Forecasters Revamp Humana Expectations Ahead Of Q3 Earnings

stocknewsapi

HUM

Humana Inc. (NYSE:HUM) will release earnings results for the third quarter before the opening bell on Wednesday, Nov. 5.

Analysts expect the Louisville, Kentucky-based company to report quarterly earnings at $2.82 per share, down from $4.16 per share in the year-ago period. The consensus estimate for Humana's quarterly revenue is $32.01 billion, compared to $29.4 billion a year earlier, according to Benzinga Pro.

On Oct. 28, Humana announced that its board declared a cash dividend to stockholders of 88.5 cents per share.

Shares of Humana rose 0.7% to close at $281.87 on Tuesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

B of A Securities analyst Kevin Fishbeck maintained a Neutral rating and raised the price target from $280 to $300 on Oct. 10, 2025. This analyst has an accuracy rate of 66%.
Mizuho analyst Ann Hynes maintained an Outperform rating and increased the price target from $300 to $345 on Oct. 9, 2025. This analyst has an accuracy rate of 72%.
Barclays analyst Andrew Mok maintained an Equal-Weight rating and cur the price target from $315 to $245 on Oct. 3, 2025. This analyst has an accuracy rate of 62%.
RBC Capital analyst Ben Hendrix maintained an Outperform rating and increased the price target from $283 to $322 on Aug. 21, 2025. This analyst has an accuracy rate of 62%.
Argus Research analyst David Toung reiterated a Hold rating with a price target of $281.99 on Aug. 14, 2025. This analyst has an accuracy rate of 67%
Considering buying HUM stock? Here’s what analysts think:

Read This Next:

Top 2 Industrials Stocks You May Want To Dump This Quarter
Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

2025-11-05 08:24 4mo ago

2025-11-05 03:00 4mo ago

Corero Network Security Builds on Q3 Execution with Major Q4 Wins and Product Breakthroughs

stocknewsapi

DDOSF

Major customer renewal, global expansion, and new innovations position Corero for continued growth into 2026 LONDON , Nov. 5, 2025 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today reported accelerating global growth in Q3 2025, fueled by rising order intake and continued innovation across its SmartWall ONE™ platform, and began Q4 with a major renewal and expansion with a leading US cloud computing provider. Building on strong execution, Corero achieved $7.4 million in Q3 order intake (up from $6.0 million in Q3 2024) with new customer wins spanning the US, UK, Europe, Brazil, and Singapore.

2025-11-05 08:24 4mo ago

2025-11-05 03:00 4mo ago

Futu to Report Third Quarter 2025 Financial Results on November 18, 2025

stocknewsapi

FUTU

November 05, 2025 03:00 ET

| Source:

Futu Holdings Limited

HONG KONG, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Futu Holdings Limited (“Futu” or the “Company”) (Nasdaq: FUTU), a leading tech-driven online brokerage and wealth management platform, today announced that it will report its financial results for the third quarter ended September 30, 2025, before U.S. markets open on November 18, 2025.

Futu's management will hold an earnings conference call on Tuesday, November 18, 2025, at 7:30 AM U.S. Eastern Time (8:30 PM on the same day, Beijing/Hong Kong Time).

Please note that all participants will need to pre-register for the conference call, using the link

https://register-conf.media-server.com/register/BI87ab49c568d44b2da54051280cc03405.

It will automatically lead to the registration page of "Futu Holdings Ltd Third Quarter 2025 Earnings Conference Call," where details for RSVP are needed.

Upon registering, all participants will be provided in confirmation emails with participant dial-in numbers and personal PINs to access the conference call. Please dial in 10 minutes prior to the call start time using the conference access information.

Additionally, a live and archived webcast of this conference call will be available at https://ir.futuholdings.com/.

About Futu Holdings Limited

Futu Holdings Limited (Nasdaq: FUTU) is an advanced technology company transforming the investing experience by offering fully digitalized financial services. Through its proprietary digital platforms, Futubull and moomoo, the Company provides a full range of investment services, including trade execution and clearing, margin financing and securities lending, and wealth management. The Company has embedded social media tools to create a network centered around its users and provide connectivity to users, investors, companies, analysts, media and key opinion leaders. The Company also provides corporate services, including IPO distribution, investor relations and ESOP solution services.

Investor Contact

Investor Relations
Futu Holdings Limited
[email protected]

2025-11-05 08:24 4mo ago

2025-11-05 03:01 4mo ago

Zscaler ThreatLabz Reveals 67% Jump in Android Malware and 40% of IoT Attacks Target Critical Industries and Hybrid Work

stocknewsapi

Key Findings:

Critical infrastructure in the energy sector experienced a 387% increase in attacks compared to the previous yearIndia continues to be the top target for mobile attacks, with 26% of activityThe US remains the top target for IoT attacks, with 54% of activity SAN JOSE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, today published the findings of its Zscaler ThreatLabz 2025 Mobile, IoT, and OT Threat Report, outlining how threat actors are leveraging malware attacks and constantly evolving their tactics. The report uncovered hundreds of malicious apps in the Google Play Store that have been downloaded over 40 million times, targeting users that are searching for productivity and workflow apps. Based on Zscaler's mobile telemetry dataset, the ThreatLabz team identified several emerging mobile threats and new malicious activity, providing valuable insights to help enterprises stay ahead of attackers in a mobile-first world.

Hundreds of malicious apps downloaded over 40 million times

Similar to last year, this year we again saw threat actors developing and releasing malicious applications targeting trusted marketplaces and hybrid work environments. The result, which the report reveals is a 67% year-over-year increase in Android malware transactions, reflects the continued risks of spyware and banking malware. ThreatLabz researchers identified 239 such applications hosted on the Google Play Store, which were collectively downloaded 42 million times.

A key distribution channel for this malware was the "Tools" category, disguising malicious applications as productivity and workflow tools. This tactic capitalizes on users' trust in functionality-driven applications–a trust that is particularly strong in hybrid and remote work settings where mobile devices are integral to professional tasks.

Manufacturing remains a top target for mobile and IoT attacks

ThreatLabz's analysis of Android attack volumes reveals that the Manufacturing and Energy sectors remain prime targets for cybercriminals due to the potential for significant returns. Notably, the energy sector experienced a substantial 387% increase in attacks compared to the previous year, highlighting an escalating threat to critical infrastructure and greater exploitation of vulnerabilities within these essential industries.

In the IoT landscape, the Manufacturing and Transportation sectors continue to be the most frequently targeted verticals. This year, each sector accounted for 20.2% of all observed IoT malware attacks, collectively representing over 40% of total incidents. This marks a shift from 2024, when Manufacturing alone represented 36% of total incidents, followed by Transportation at 14%. This suggests that while Manufacturing remains a critical target, threat actors are increasingly diversifying their efforts across other high-dependency IoT industries.

Most prevalent IoT malware

Roughly 40% of blocked transactions are linked to the Mirai family alone, and Mozi has overtaken Gafgyt as the second highest malware family. Together, Mirai, Mozi, and Gafgyt account for roughly 75% of all malicious payloads in IoT environments.

Mobile attacks cluster in India, US and Canada; US is the IoT threat epicenter at 54 percent

Worldwide, mobile threats have surged, with many of these attacks concentrated in three key regions: India, accounting for 26% of all mobile attacks, the United States at 15%, and Canada at 14%. India, in particular, experienced a significant 38% increase in mobile threat attacks compared to the previous year.

The top five countries that receive the most mobile malware traffic are:

India (26%)United States (15%)Canada (14%)Mexico (5%)South Africa (4%) The report also revealed that the US is both a hub for IoT activity (54.1%) and a primary target for malware attacks. The top five countries that receive the most IoT malware traffic are:

United States (54%)Hong Kong (15.%)Germany (6%)India (5%)China (4%) “Attackers are pivoting to areas with maximum impact. We’re seeing a YoY rise of 67% in malware targeting mobile devices and 387% in IoT/OT attacks on energy sectors often hosting critical infrastructure, which is a massive swing,” said Deepen Desai, EVP and Chief Security Officer at Zscaler. “A Zero Trust everywhere approach, combined with AI-powered threat detection, is imperative to reducing the attack surface, limit lateral movement, and provide organizations the defense they need against ever-evolving attacks.”

Additional highlights and new findings this year

A new backdoor called Android Void malware has infected 1.6 million Android-based TV boxes, primarily in India and BrazilNew Remote Access Trojan (RAT), Xnotice, was identified for targeting job seekers in the oil and gas industry, particularly in MENAAdware overtook the Joker malware family as the top mobile threat, with a leading 69% of cases, while Joker dropped to 23% of cases, from 38% last yearThreat actors are abandoning card-focused fraud in favor of mobile payments Defending against growing IoT, OT and Mobile threats

Zscaler Zero Trust Branch delivers comprehensive security and operational efficiency for branch offices, remote sites, and distributed networks, designed for environments that rely heavily on mobile, IoT, cellular IoT, and OT technologies. Using a cloud-native and AI-driven Zero Trust architecture, Zscaler aims to ensure all users, devices, and applications are safeguarded with continuous real-time verification and robust policy enforcement, regardless of their location relative to the traditional network perimeter.

Zscaler Cellular offers secure, scalable, and efficient connectivity as a service for IoT and mobile devices that rely on cellular connections. This solution, powered by the Zscaler Zero Trust Exchange™ platform, addresses the growing security challenges posed by billions of IoT devices and mobile endpoints, which traditional security methods often fail to secure effectively. It achieves this by enforcing granular policies, providing centralized visibility, and eliminating attack surfaces for all cellular traffic.

Download your copy

The 2025 Mobile, IoT, and OT Threat Report highlights the critical importance of securing mobile endpoints, IoT devices, and OT systems. Access the full report at https://www.zscaler.com/campaign/threatlabz-mobile-iot-ot-report.

Research Methodology
Mobile
The research methodology for this report includes analysis of mobile transactions and associated cyberthreats based on data collected from the Zscaler cloud between June 2024 and May 2025. The dataset comprises more than 20 million threat-related mobile transactions.

IoT/OT
The team focused their research on understanding the distinct attributes and activity of IoT devices via device fingerprinting (DFP) and analyzing the IoT malware threat landscape.

Device fingerprinting data from March 2025 to May 2025 included:

A complete inventory of devices, including device types and manufacturersThe volume and source of IoT device transactionsThe industries and geographies contributing to IoT traffic IoT malware threat data from June 2024 to May 2025 included:

The most active malware familiesThe industries and geographies most targeted by IoT attacksThe top attacked devices About Zscaler
Zscaler (NASDAQ: ZS) accelerates digital transformation so customers can be more agile, efficient, resilient, and secure. The Zscaler Zero Trust Exchange™ platform protects thousands of customers from cyberattacks and data loss by securely connecting users, devices, and applications in any location. Distributed across more than 160 data centers globally, the SASE-based Zero Trust Exchange is the world’s largest in-line cloud security platform.

Media Contact
Taylor Dunton, Senior Director, Public Relations, [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a9909238-c36f-4286-a7b6-5916db8e5847

Threatlabz 2025 Mobile, IoT, and OT Threat Report
2025 Threatlabz Mobile, IoT, and OT Threat Report-

2025-11-05 08:24 4mo ago

2025-11-05 03:05 4mo ago

Point and Funds Managed by Blue Owl Capital Close Oversubscribed $390 Million Home Equity Investment Rated Securitization

stocknewsapi

OWL

Palo Alto, California, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Point, the leading home equity investment platform making homeownership more valuable and accessible, and funds managed by Blue Owl Capital (“Blue Owl”) announced today that they have completed a rated securitization of Point’s Home Equity Investment (“HEI”) assets, issuing $390 million of rated asset-backed securities (the “Transaction”), marking Point’s third securitization of 2025 and continuing the firm’s record of programmatic issuance.

The Transaction closed on October 28th, 2025. The issuer, Point Securitization Trust 2025-2, issued $254.2 million of senior class A-1 securities rated A (low) (sf), $46.6 million of mezzanine class A-2 securities rated BBB (low) (sf), $45.9 million of subordinate class B-1 securities rated BB (low) (sf), and $43.3 million of subordinate class B-2 securities rated B (high) (sf) (retained), all rated by Morningstar DBRS. A portion of the notes was acquired by accounts managed by an affiliate of Blue Owl. The Transaction attracted 29 unique investors, including eight new entrants to the Point securitization platform, resulting in over $1.6 billion in orders, and underscoring the continued institutional interest and confidence in Point’s program. Co-sponsoring the Transaction with a subsidiary of Blue Owl, Point was the originator of all the HEIs in the securitization and will continue to service the assets.

In addition to complying with U.S. credit risk retention rules, the Transaction is the first HEI securitization to include undertakings related to both the EU Securitization Regulation and the UK Securitization Framework, as well as the transparency requirements of the EU Securitization Regulation. These steps further position Point’s securitization platform to meet the standards of European and UK institutional investors, reflecting Point’s commitment to broadening global access to the HEI market.

“Building on the strong momentum of PNT 25-1, this transaction reflects growing confidence in home equity investments as a mainstream asset class,” said Eddie Lim, co-founder and CEO of Point. “As homeowners and investors continue to seek flexible, sustainable ways to unlock and deploy capital, Point is proud to lead with consistency, transparency, and execution.”

Since pioneering the HEI category in 2015, Point has closed six securitizations and continues to set benchmarks for liquidity, scalability, and transparency in alternative home equity financing.

“This marks the third transaction that Blue Owl has co-sponsored alongside Point. We were able to combine legacy seasoned collateral we acquired earlier this year with new originations purchased directly from Point to issue the largest public HEI securitization to date,” said Ivan Zinn, Head of Alternative Credit at Blue Owl. “Blue Owl and Point have a longstanding relationship dating back to 2018, and we are excited to continue working with the Point team.”

Barclays Capital Inc. (“Barclays”) was the sole-structuring agent for the issuance. Barclays, Nomura Securities International Inc., and Cantor Fitzgerald & Co. were joint bookrunners on the Transaction, and East West Markets, LLC and StoneX Financial Inc. were co-managers on the Transaction.

About Point

Point is the leading home equity platform making homeownership more valuable and accessible. Point’s flagship product, the Home Equity Investment (HEI), empowers homeowners to unlock their equity to eliminate debt, get through periods of financial hardship, and diversify their wealth – without adding to their monthly expenses. Point has worked with more than 15,000 homeowners, unlocking more than $1.5 billion in home equity. Point’s HEI enables investors to access a previously untapped asset class – owner-occupied residential real estate. Founded in 2015 by Eddie Lim, Eoin Matthews, and Alex Rampell, Point is backed by top investors, including Westcap, Andreessen Horowitz, Ribbit Capital, Greylock Partners, Bloomberg Beta, Blue Owl Capital, Alpaca VC, and Prudential. The company is headquartered in Palo Alto, CA. For more information, please visit www.point.com

About Blue Owl

Blue Owl (NYSE: OWL) is a leading asset manager that is redefining alternatives®. With over $295 billion in assets under management as of September 30, 2025, we invest across three multi-strategy platforms: Credit, Real Assets and GP Strategic Capital. Anchored by a strong permanent capital base, we provide businesses with private capital solutions to drive long-term growth and offer institutional investors, individual investors, and insurance companies differentiated alternative investment opportunities that aim to deliver strong performance, risk-adjusted returns, and capital preservation.

Together with over 1,365 experienced professionals globally, Blue Owl brings the vision and discipline to create the exceptional. To learn more, visit www.blueowl.com.

2025-11-05 08:24 4mo ago

2025-11-05 03:13 4mo ago

Marks & Spencer Profits Plummet on Cyberattack

stocknewsapi

MAKSY

Adjusted pretax profit plunged 55%, but the retailer said it expects a recovery in the second half of its fiscal year.

2025-11-05 08:24 4mo ago

2025-11-05 03:14 4mo ago

ONEOK: Get Ready For A Stronger Rally

stocknewsapi

OKE

2025-11-05 08:24 4mo ago

2025-11-05 03:15 4mo ago

E3 Lithium to Host Webinar on November 5, 2025 @ 9:00AM MT

stocknewsapi

EEMMF

CALGARY, Alberta--(BUSINESS WIRE)--E3 LITHIUM LTD. (TSXV: ETL) (FSE: OW3) (OTCQX: EEMMF), (“E3 Lithium” or the “Company”) a leader in Canadian lithium development, reminds shareholders and interested stakeholders the Company is hosting a Webinar this morning, November 5, 2025, at 9:00am MT. During the presentation, Chris Doornbos, President and CEO, and members of the E3 Lithium management team will discuss:

Summary of Phase 1 Demonstration Facility achievements

Update on Phase 2 Demonstration Facility progress

Review of the recently closed equity financing

Positioning of E3 Lithium within the North American critical minerals strategy

Recent federal and provincial government initiatives supporting lithium development

Upcoming milestones for the Clearwater Project for Q4 2025 and 2026

Webinar Details:

Date: Wednesday, November 5, 2025

Time: 09:00 AM Mountain Time (11:00 AM Eastern Time)

Registration Link: Zoom (click here to log in at the time of the webinar; no need to register in advance)

Duration: 45 minutes presentation + 15 minutes Q&A

If you are having issues with the registration link, copy this address into your browser to be directed to the log in page: https://us02web.zoom.us/webinar/register/WN_o022pANsTUSsiD6uPUdTag

The webinar will be followed by a live Q&A session where attendees can submit questions in real-time. Participants are encouraged to submit questions in advance by emailing [email protected] to ensure they are reviewed during the webinar.

The webinar recording will be made available on the Company's website following the event.

ON BEHALF OF THE BOARD OF DIRECTORS

Chris Doornbos, President, CEO & Chair

E3 Lithium Ltd.

About E3 Lithium

E3 Lithium is a development company with a total of 21.2 million tonnes (Mt) of lithium carbonate equivalent (LCE) Measured and Indicated1 resources as well as 0.3 Mt LCE Inferred mineral resources2 in Alberta and 2.5 Mt LCE Inferred mineral resources3 in Saskatchewan. The Clearwater Project Pre-Feasibility Study outlined a 1.13 Mt LCE proven and probable mineral reserve with a pre-tax NPV(8%) of USD 5.2 Billion with a 29.2% IRR and an after-tax NPV(8%) of USD 3.7 Billion with a 24.6% IRR1.

1: The Clearwater Project NI 43-101 Pre-Feasibility Study, effective June 20, 2024 (the “PFS”), identified 16.2 Mt LCE (measured and indicated) and is available on the E3 Lithium website (www.e3lithium.ca/technical-reports/) and SEDAR+ (www.sedarplus.ca).

2: The mineral resource NI 43-101 Technical Report for the Garrington District Lithium Resource Estimate, effective June 25, 2025, identified 5.0 Mt LCE (measured and indicated) and 0.3 Mt LCE (inferred) and is available on the E3 Lithium website (www.e3lithium.ca/technical-reports/) and SEDAR+ (www.sedarplus.ca).

3: The mineral resource NI 43-101 Technical Report for the Estevan Lithium District, effective May 23, 2024, identified 2.5 Mt LCE (inferred) and is available on the E3 Lithium website (www.e3lithium.ca/technical-reports/) and SEDAR+ (www.sedarplus.ca).

Unless otherwise indicated, Kevin Carroll, P. Eng., Chief Development Officer and a Qualified Person under National Instrument 43-101, has reviewed and is responsible for the technical information contained on this news release.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions or forward-looking information within the meaning of applicable securities laws. Forward-looking statements are frequently identified by such words as “believe”, “may”, “will”, “plan”, “expect”, “anticipate”, “estimate”, “intend”, “project”, “potential”, “possible” and similar words referring to future events and results. Forward-looking statements are based on the current opinions, expectations, estimates and assumptions of management in light of its experience, and perception of historical trends, but such statements are not guarantees of future performance. All forward-looking information (including future-orientated financial information) is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of mineral exploration and development, fluctuating commodity prices, the effectiveness and feasibility of emerging lithium extraction technologies which have not yet been tested or proven on a commercial scale or on the Company’s brine, risks related to the availability of financing on commercially reasonable terms and the expected use of proceeds; operations and contractual obligations; changes in estimated mineral reserves or mineral resources; future prices of lithium and other metals; availability of third party contractors; availability of equipment; failure of equipment to operate as anticipated; accidents, effects of weather and other natural phenomena and other risks associated with the mineral exploration industry; the Company’s lack of operating revenues; currency fluctuations; risks related to dependence on key personnel; estimates used in financial statements proving to be incorrect; competitive risks and the availability of financing, as described in more detail in our recent securities filings available under the Company’s profile on SEDAR+ (www.sedarplus.ca). Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.

More News From E3 LITHIUM LTD.

2025-11-05 08:24 4mo ago

2025-11-05 03:16 4mo ago

Paylocity Holding Corporation (PCTY) Q1 2026 Earnings Call Transcript

stocknewsapi

PCTY

Q1: 2025-11-04 Earnings SummaryEPS of $1.75 beats by $0.18

|

Revenue of

$408.17M

(12.46% Y/Y)

beats by $8.64M

Paylocity Holding Corporation (PCTY) Q1 2026 Earnings Call November 4, 2025 5:00 PM EST

Company Participants

Ryan Glenn - Chief Financial Officer
Steven Beauchamp - Executive Chairman of the Board
Toby Williams - President, CEO & Director

Conference Call Participants

Brad Reback - Stifel, Nicolaus & Company, Incorporated, Research Division
Mark Marcon - Robert W. Baird & Co. Incorporated, Research Division
Daniel Jester - BMO Capital Markets Equity Research
Connor Passarella
Sitikantha Panigrahi - Mizuho Securities USA LLC, Research Division
Sheldon McMeans - Barclays Bank PLC, Research Division
Jared Levine - TD Cowen, Research Division
Jacob Roberge - William Blair & Company L.L.C., Research Division
Ian Black
Jordan Boretz
Jessica Wang - Raymond James & Associates, Inc., Research Division
Kincaid LaCorte
Aleksandr Zukin - Wolfe Research, LLC
Matthew VanVliet - Cantor Fitzgerald & Co., Research Division
Jason Celino - KeyBanc Capital Markets Inc., Research Division
George Michael Kurosawa - Citigroup Inc., Research Division
Zachary Gunn - Financial Technology Partners LP
Madeline Brooks
Jacob Cody Smith - Guggenheim Securities, LLC, Research Division

Presentation

Operator

Good day, and thank you for standing by. Welcome to the Paylocity Holding Corporation First Quarter 2026 Fiscal Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Ryan Glenn, Chief Financial Officer. Please go ahead.

Ryan Glenn
Chief Financial Officer

Good afternoon, and welcome to Paylocity's earnings results call for the first quarter of fiscal '26, which ended on September 30, 2025. I'm Ryan Glenn, Chief Financial Officer. And joining me on the call today are Steve Beauchamp, Executive Chairman; and Toby Williams, President and CEO of Paylocity. Today, we will be discussing the results announced in our press release issued after the market closed. A webcast replay of this call will be available for the next 45 days on our website under the Investor Relations tab.

Recommended For You

2025-11-05 08:24 4mo ago

2025-11-05 03:16 4mo ago

AGC Inc. (ASGLY) Q3 2025 Earnings Call Transcript

stocknewsapi

ASGLY

AGC Inc. (OTCPK:ASGLY) Q3 2025 Earnings Call November 5, 2025 1:00 AM EST

Company Participants

Kazumi Tamaki - Executive Officer and GM of Corporate Communications & Investor Relations
Shinji Miyaji - Senior EVP, CFO, CCO & Director

Presentation

Kazumi Tamaki
Executive Officer and GM of Corporate Communications & Investor Relations

Let us get started. Welcome to the earnings briefing of AGC Inc. for the third quarter of fiscal year 2025. I'm Kazumi Tamaki, General Manager, Corporate Communications and Investor Relations, serving as moderator. Today's attendees are Shinji Miyaji, Executive Vice President, Executive Officer and CFO; and Tomoyuki Shiokawa, Executive Officer, General Manager of Finance and Control Division. We will first have CFO Miyaji, provide an overview of the financial results for the third quarter, followed by a Q&A session. We are planning to finish at 3:45 p.m. Your cooperation is appreciated.

Without further ado, I ask CFO, Miyaji, to start his presentation.

Shinji Miyaji
Senior EVP, CFO, CCO & Director

Thank you. This is Shinji Miyaji, the CFO. Please turn to Page 3. The highlights. Net sales for the first 9 months totaled JPY 1,512.1 billion, down JPY 22.1 billion year-on-year. Positives included an improved product mix and pricing policies for automotive glass, increased shipments and pricing policies for Performance Chemicals and pricing policies for architectural glass in Europe and the Americas, while negatives included a PVC price decline, decreased shipments of EUV photo blanks and European architectural glass and the impact of last year's Russian business transfer.

Operating profit was JPY 94.8 billion, up JPY 0.8 billion on effects of profit improvement measures in displays and others despite the adverse impact of the aforementioned factors as well as higher raw materials and fuel costs. Net income attributable to the owners of the parent was up JPY 145.9 billion at JPY 39.5 billion

Recommended For You

2025-11-05 08:24 4mo ago

2025-11-05 03:17 4mo ago

Google's $32 billion deal for Wiz clears DOJ antitrust review, Wiz CEO tells WSJ

stocknewsapi

GOOG GOOGL

The Google logo is pictured at the entrance to the Google offices in London, Britain January 18, 2019. REUTERS/Hannah McKay Purchase Licensing Rights, opens new tab

Nov 5 (Reuters) - Cybersecurity company Wiz has cleared a U.S. Justice Department (DOJ) antitrust review of its acquisition by Google-parent Alphabet

(GOOGL.O), opens new tab, Wiz CEO said in a Wall Street Journal event on Tuesday.

The deal, valued at about $32 billion, would be Alphabet's largest acquisition. It will integrate Wiz into Google's cloud unit, enhancing the company's cybersecurity solutions to help businesses mitigate critical risks.

Sign up here.

"Definitely, this is an important milestone, but we’re still in the journey between signing and closing," Wiz CEO Assaf Rappaport said, when asked about the DOJ review of the deal.

In June, Bloomberg had reported that the DOJ antitrust enforcers were reviewing whether Alphabet's planned acquisition the cybersecurity firm would illegally limit competition in the marketplace.

"We look forward to completing the review process in other jurisdictions. The acquisition of Wiz is expected to close in 2026, subject to customary closing conditions," a Google spokesperson told Reuters in an emailed statement.

The DOJ and Wiz did not immediately respond to Reuters requests for comment.

Reporting by Abu Sultan and Devika Nair in Bengaluru, Editing by Eileen Soreng

Our Standards: The Thomson Reuters Trust Principles., opens new tab

2025-11-05 08:24 4mo ago

2025-11-05 03:21 4mo ago

Marks & Spencer steadies the ship after cyber attack. But questions linger over recovery pace

stocknewsapi

MAKSY

Marks and Spencer Group PLC (LSE:MKS) shares slipped about 3% in early trading despite results that analysts described as “better than feared,” following a turbulent six months dominated by a major cyber attack that knocked its online operations offline for 46 days.

The retailer reported adjusted pre-tax profit of £184 million for the first half of its financial year, a sharp fall from £413 million a year ago but comfortably ahead of analysts’ forecasts of around £76 million.

That figure was boosted by a prompt £100 million insurance payout covering losses from the cyber incident in April, which crippled the group’s website and led to weeks of restricted trading.

Even so, the results underline how far M&S has come since its near-collapse a decade ago.

Shore Capital, which acts as house broker, said weaker businesses “would not have emerged as robust as M&S to the malevolent challenges” it faced this year.

The company expects to be back to full operational strength by the end of the current financial year, with its food division already close to pre-attack performance levels.

Chief executive Stuart Machin said the group had “so much more to do and so much opportunity ahead,” but the immediate focus remains on restoring momentum in its fashion and home arm, which was hit hardest when online trading stopped.

Food sales rose 7.8% in the half-year, helped by more shoppers and new product launches, though margins were squeezed by markdowns and waste.

By contrast, fashion, home and beauty sales fell 16% after online orders plunged 42%. The division’s operating profit tumbled to £46 million from £243 million a year earlier.

ShoreCap expects full-year adjusted pre-tax profit of £655 million, including the insurance settlement, and at least flat profit growth in the second half compared with last year’s £468 million. Underlying profit, excluding the payout, is forecast at £555 million.

The company raised its interim dividend by 20% to 1.2p a share, a move analysts said demonstrated management’s confidence in cash flow. Net cash stood at £176 million, although total debt, including leases, increased slightly to £2.5 billion.

Despite the disruption, M&S is pushing ahead with its store renewal programme. Fifteen shops opened in the first half, with another 20 planned by year-end, including two new full-line outlets in Bath and Bristol.

Investment in logistics and technology is also continuing, including a £340 million food distribution centre in Daventry set to open in 2029.

Still, the road ahead looks far from certain. ShoreCap trimmed its 2027 profit forecast by 2.5% amid fears of higher taxes and softer consumer demand after Chancellor Rachel Reeves’ warning that “we are all in this together". This is seen as a prelude to a Tresury raid on earnings.

M&S shares, at about 374p (down 10.5p), trade on roughly 11 times expected 2027 earnings, a discount to Next and Tesco. Analysts argue that ongoing progress could narrow that gap.

For now, today’s dip in the share price suggests investors are reserving judgment.

M&S may have weathered the cyber storm better than expected, but the next few months will show whether it can fully reclaim the digital momentum it worked so hard to build.

2025-11-05 07:24 4mo ago

2025-11-05 01:46 4mo ago

Soleno Therapeutics, Inc. (SLNO) Q3 2025 Earnings Call Transcript

stocknewsapi

SLNO

Soleno Therapeutics, Inc. (SLNO) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST

Company Participants

Anish Bhatnagar - Chairman, President, CEO & COO
Meredith Manning - Chief Commercial Officer
James MacKaness - CFO & Compliance Officer

Conference Call Participants

Brian Ritchie - Lifesci Advisors, LLC
Kyuwon Choi - Goldman Sachs Group, Inc., Research Division
Tyler Van Buren - TD Cowen, Research Division
Moritz Reiterer - Guggenheim Securities, LLC, Research Division
Rick Miller - Cantor Fitzgerald & Co., Research Division
Yasmeen Rahimi - Piper Sandler & Co., Research Division
Leland Gershell - Oppenheimer & Co. Inc., Research Division
Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division
James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division
Derek Archila - Wells Fargo Securities, LLC, Research Division
Yale Jen - Laidlaw & Company (UK) Ltd., Research Division
Katherine Dellorusso
Jade Montgomery

Presentation

Operator

Good afternoon, and thank you for standing by. Welcome to Soleno Therapeutics Third Quarter 2025 Financial and Operating Results Conference Call and webcast. [Operator Instructions]. As a reminder, today's webcast is being recorded.

I would now like to introduce Brian Ritchie of LifeSci Advisors. Please go ahead.

Brian Ritchie
Lifesci Advisors, LLC

Thank you. Good afternoon, everyone, and thank you for joining us to discuss Soleno Therapeutics Third Quarter 2025 financial and operating results.

Please note, we will be making certain forward-looking statements today. We refer you to Soleno's SEC filings for a discussion of the risks that may cause actual results to differ from the forward-looking statements.

On the call with me today for Soleno are Anish Bhatnagar, Soleno's Chairman and Chief Executive Officer; Meredith Manning, Soleno's Chief Commercial Officer; and Jim MacKaness, Soleno's Chief Financial Officer.

With that, I will now turn the call over to Anish.

Anish Bhatnagar
Chairman, President, CEO & COO

Thank you, Brian, and thank you, everyone, for joining us for our third quarter results call

Recommended For You

2025-11-05 07:24 4mo ago

2025-11-05 01:47 4mo ago

Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount

stocknewsapi

NVO

Danish pharmaceutical giant Novo Nordisk said Wednesday it is lowering its growth expectations for its key obesity and diabetes treatments.

Net profit for the quarter came in at 20 billion Danish kroner ($3.1 billion) in line with the 20.12 billion Danish kroner anticipated by analysts in a FactSet poll.

Diabetes and obesity care were a key growth driver following the uptake of Wegovy and Ozempic, however the company lowered its expectations for growth, citing prescription trends, competition and pricing pressure.

Sales of its blockbuster weight loss drug Wegovy rose 18% year-on-year to hit 20.35 billion Danish kroner in the three months to September, slightly below the 21.35 billion kroner expected by analysts.

watch now

Novo's Copenhagen-listed shares have tumbled more than 50% over the course of this year, as a slew of headwinds has shaken investor confidence in what was once Europe's most valuable firm.

Stock Chart IconStock chart icon

Novo Nordisk share price

Alongside a series of disappointing trial results, increasing competition in the obesity drug space and challenges arising from U.S. policies on drug pricing and tariffs, Novo has been contending with leadership shakeups and pushback against a key acquisition.

Analysts, as a result, have been mixed on the stock. Jefferies recently cut its rating to underperform while Berenberg is positive on the stock, saying Novo has hit "peak uncertainty."

"Novo's superior growth profile and best-in-class R&D returns warrants a higher valuation premium to its peers," the bank said.

Metsera bidNovo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from U.S. pharma giant Pfizer. On Monday, Pfizer said it had filed a second lawsuit against Novo and Metsera, arguing that Novo's bid for the smaller company was anticompetitive.

A spokesperson for Novo said in a statement that Pfizer's allegations were "false and without merit."

Novo then ramped up its bid for Metsera on Tuesday, saying it was now offering up to $10 billion compared to the earlier offer of around $9 billion.

"Novo Nordisk believes that the proposal, including the structure of the transaction, complies with all applicable laws and is in the best interest of patients who will benefit from our commitment to innovation, as well as Metsera's shareholders," the company said in a statement, noting that the deal was also subject to the term's of Pfizer's merger agreement with Metsera.

Metsera said on Tuesday that the revised offer was "superior" to a revised bid made by Pfizer.

2025-11-05 07:24 4mo ago

2025-11-05 01:48 4mo ago

Siemens Healthineers Reports Fall in Profits, Citing Tariffs

stocknewsapi

SMMNY

Higher comparable revenue stemming from the transformation program of its diagnostics business was offset by a hit from U.S. tariffs.